

Combining immunotherapy and targeted therapies in c

Nature Reviews Cancer

12, 237-251

DOI: [10.1038/nrc3237](https://doi.org/10.1038/nrc3237)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. <i>Frontiers in Physiology</i> , 2012, 3, 270.	1.3	64
2	Cancer battlefield: six characters in search of an author. <i>Immunotherapy</i> , 2012, 4, 753-755.	1.0	2
3	Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice. <i>Oncolmunology</i> , 2012, 1, 1038-1047.	2.1	22
4	Trial watch. <i>Oncolmunology</i> , 2012, 1, 1557-1576.	2.1	110
5	Strategies for Enhancing Vaccine-Induced CTL Antitumor Immune Responses. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-9.	3.0	13
6	Oncolytic Viruses in the Treatment of Cancer: A Review of Current Strategies. <i>Pathology and Oncology Research</i> , 2012, 18, 771-781.	0.9	52
7	Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. <i>Nanoscale</i> , 2012, 4, 7021.	2.8	144
8	Tailor-Made Renal Cell Carcinoma Vaccines. <i>Cancer Cell</i> , 2012, 22, 287-289.	7.7	3
9	Overview of cancer vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1335-1353.	1.4	19
10	Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. <i>Nature Biotechnology</i> , 2012, 30, 648-657.	9.4	95
11	Autologous Regulatory T Cells for the Treatment of Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2012, 12, 623-632.	1.7	18
12	Cancer-associated fibroblasts as targets for immunotherapy. <i>Immunotherapy</i> , 2012, 4, 1129-1138.	1.0	88
13	Cancer as an immune-mediated disease. <i>ImmunoTargets and Therapy</i> , 2012, 1, 1.	2.7	35
14	The blockade of immune checkpoints in cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2012, 12, 252-264.	12.8	10,874
15	Combinations that work. <i>Nature Reviews Cancer</i> , 2012, 12, 231-231.	12.8	4
16	Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. <i>Journal of Translational Medicine</i> , 2013, 11, 70.	1.8	28
17	Oncology Meets Immunology: The Cancer-Immunity Cycle. <i>Immunity</i> , 2013, 39, 1-10.	6.6	4,815
18	Stem Cells and Cancer Stem Cells, Volume 10. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
19	Improved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2. <i>Cancer Gene Therapy</i> , 2013, 20, 564-575.	2.2	10
20	Adaptive Immune Responses and HER2/neu-Positive Breast Cancer. <i>Current Pathobiology Reports</i> , 2013, 1, 37-42.	1.6	11
21	FOXM1 (Forkhead box M1) in Tumorigenesis. <i>Advances in Cancer Research</i> , 2013, 119, 191-419.	1.9	146
22	^{99m} Tc(N)-DBODC(5), a potential radiolabeled probe for SPECT of multidrug resistance: in vitro study. <i>Journal of Biological Inorganic Chemistry</i> , 2013, 18, 523-538.	1.1	11
23	The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis. <i>Neoplasia</i> , 2013, 15, 848-IN45.	2.3	396
24	New developments in cancer vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 1109-1110.	2.0	5
26	Immunologically augmented cancer treatment using modern radiotherapy. <i>Trends in Molecular Medicine</i> , 2013, 19, 565-582.	3.5	91
27	Microenvironmental regulation of tumor progression and metastasis. <i>Nature Medicine</i> , 2013, 19, 1423-1437.	15.2	5,730
28	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. <i>Carcinogenesis</i> , 2013, 34, 725-738.	1.3	86
29	Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions. <i>Current Oncology Reports</i> , 2013, 15, 500-508.	1.8	20
30	Immunotherapy at Large: Balancing tumor immunity and inflammatory pathology. <i>Nature Medicine</i> , 2013, 19, 1100-1101.	15.2	30
31	Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance. <i>Immunity</i> , 2013, 39, 74-88.	6.6	739
32	Adjuvant Strategies for Vaccines. , 2013, , 333-349.		4
33	Immune classification of colorectal cancer patients: impressive but how complete?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 517-526.	1.4	18
34	Therapeutic opportunities for manipulating TReg cells in autoimmunity and cancer. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 51-63.	21.5	181
35	T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2013, 25, 214-221.	2.4	576
36	Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. <i>Journal of Molecular Medicine</i> , 2013, 91, 147-155.	1.7	38
37	Challenges in cancer vaccine development for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 897-903.	1.8	87

#	ARTICLE	IF	CITATIONS
38	Targeted Therapy for Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 805-821.	0.6	12
39	Current concepts and novel targets in advanced pancreatic cancer. <i>Gut</i> , 2013, 62, 317-326.	6.1	134
40	Noncanonical roles of the immune system in eliciting oncogene addiction. <i>Current Opinion in Immunology</i> , 2013, 25, 246-258.	2.4	11
41	Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1989-1992.	1.0	34
42	Molecular mechanisms of T cell co-stimulation and co-inhibition. <i>Nature Reviews Immunology</i> , 2013, 13, 227-242.	10.6	2,382
43	Interaction of tumor cells with the immune system: implications for dendritic cell therapy and cancer progression. <i>Drug Discovery Today</i> , 2013, 18, 35-42.	3.2	7
44	Hyaluronic Acid-Based Nanogelâ€“Drug Conjugates with Enhanced Anticancer Activity Designed for the Targeting of CD44-Positive and Drug-Resistant Tumors. <i>Bioconjugate Chemistry</i> , 2013, 24, 658-668.	1.8	171
45	Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas. <i>British Journal of Cancer</i> , 2013, 108, 1449-1459.	2.9	57
46	HRas Signal Transduction Promotes Hepatitis C Virus Cell Entry by Triggering Assembly of the Host Tetraspanin Receptor Complex. <i>Cell Host and Microbe</i> , 2013, 13, 302-313.	5.1	141
47	Cancer Gene Therapy with Small Oligonucleotides. , 0, , .		1
48	Immune checkpoint blockade immunotherapy to activate antiâ€“tumour <scp>T</scp>â€“cell immunity. <i>British Journal of Haematology</i> , 2013, 162, 313-325.	1.2	102
49	Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. <i>Current Opinion in Immunology</i> , 2013, 25, 192-199.	2.4	76
50	<i>In Vivo</i> Targeting of Intratumor Regulatory T Cells Using PEG-Modified Single-Walled Carbon Nanotubes. <i>Bioconjugate Chemistry</i> , 2013, 24, 852-858.	1.8	81
51	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 233-247.	1.1	38
52	Targeting the Bcl-2 family for cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 61-75.	1.5	213
53	Targeted cancer immunotherapy. <i>Current Opinion in Pharmacology</i> , 2013, 13, 504-510.	1.7	30
54	Generation of Antigen-Specific T Lymphocytes from Induced Pluripotent Stem Cells for Adoptive Immunotherapy. , 2013, , 105-121.		0
55	Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date. <i>Drugs</i> , 2013, 73, 767-777.	4.9	11

#	ARTICLE	IF	CITATIONS
56	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e23803.	2.1	92
57	Photochemical targeting of antigens to the cytosol for stimulation of MHC class-I-restricted T-cell responses. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 34-41.	2.0	20
58	Recent advances in the treatment of metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2013, 20, 944-955.	0.5	54
59	The oxysterolâ€“CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. <i>Journal of Experimental Medicine</i> , 2013, 210, 1711-1728.	4.2	167
60	Emerging Therapeutic Biomarkers in Endometrial Cancer. <i>BioMed Research International</i> , 2013, 2013, 1-11.	0.9	49
61	Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. <i>Frontiers in Immunology</i> , 2013, 4, 438.	2.2	289
62	Immunotherapy and Immune Evasion in Prostate Cancer. <i>Cancers</i> , 2013, 5, 569-590.	1.7	19
63	Therapeutic Dendritic Cell-Based Cancer Vaccines: The State of the Art. <i>Critical Reviews in Immunology</i> , 2013, 33, 489-547.	1.0	36
64	Nano-Curcumin Inhibits Proliferation of Esophageal Adenocarcinoma Cells and Enhances the T Cell Mediated Immune Response. <i>Frontiers in Oncology</i> , 2013, 3, 137.	1.3	51
65	Risk Factors and Therapeutic Targets in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 282.	1.3	38
66	Current trends of anticancer immunochemotherapy. <i>Oncolimmunology</i> , 2013, 2, e25396.	2.1	26
67	Current status of immunotherapy for the treatment of biliary tract cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1069-1072.	1.4	18
68	The impact of molecular targets in cancer drug development: major hurdles and future strategies. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 23-34.	1.3	19
69	Transnuclear TRP1-Specific CD8 T Cells with High or Low Affinity TCRs Show Equivalent Antitumor Activity. <i>Cancer Immunology Research</i> , 2013, 1, 99-111.	1.6	45
70	The Arf/p53 Protein Module, Which Induces Apoptosis, Down-regulates Histone H2AX to Allow Normal Cells to Survive in the Presence of Anti-cancer Drugs. <i>Journal of Biological Chemistry</i> , 2013, 288, 13269-13277.	1.6	26
71	Sunitinib, a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Suppresses Neointimal Hyperplasia in Balloon-Injured Rat Carotid Artery. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 359-366.	1.0	12
72	Beyond the Antigen Receptor: Editing the Genome of T-Cells for Cancer Adoptive Cellular Therapies. <i>Frontiers in Immunology</i> , 2013, 4, 221.	2.2	37
73	TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic. <i>Frontiers in Immunology</i> , 2013, 4, 473.	2.2	42

#	ARTICLE	IF	CITATIONS
74	Improving the Therapeutic Potential of Human Granzyme B for Targeted Cancer Therapy. <i>Antibodies</i> , 2013, 2, 19-49.	1.2	21
75	Chitin, Chitosan, and Glycated Chitosan Regulate Immune Responses: The Novel Adjuvants for Cancer Vaccine. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	114
76	Selective Inhibition of Phosphoinositide 3-Kinase p110 α Preserves Lymphocyte Function*. <i>Journal of Biological Chemistry</i> , 2013, 288, 5718-5731.	1.6	60
77	Trial Watch. <i>Oncolmunology</i> , 2013, 2, e25595.	2.1	83
78	Effects of conventional therapeutic interventions on the number and function of regulatory T cells. <i>Oncolmunology</i> , 2013, 2, e27025.	2.1	148
79	Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2013, 19, 1858-1872.	3.2	272
80	Challenges and Opportunities for Cancer Vaccines in the Current NSCLC Clinical Scenario. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 2551-2561.	1.0	4
81	Targeting immunosuppression for cancer therapy. <i>Journal of Clinical Investigation</i> , 2013, 123, 2355-2357.	3.9	53
82	Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights. , 2013, , .		0
83	Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. <i>International Journal of Nanomedicine</i> , 2013, 8, 2677.	3.3	83
84	Cancer testis antigen and immunotherapy. <i>ImmunoTargets and Therapy</i> , 2013, 2, 11.	2.7	43
85	Effects of Novel Isoform-Selective Phosphoinositide 3-Kinase Inhibitors on Natural Killer Cell Function. <i>PLoS ONE</i> , 2014, 9, e99486.	1.1	11
86	Nanocarrier-based immunotherapy in cancer management and research. <i>ImmunoTargets and Therapy</i> , 2014, 3, 121.	2.7	18
87	Mesoporous Magnetic Gold Nanoclusters as Theranostic Carrier for Chemo-Photothermal Co-therapy of Breast Cancer. <i>Theranostics</i> , 2014, 4, 678-692.	4.6	103
88	T Lymphocyte Antigen 4-Modified Dendritic Cell Therapy for Asthmatic Mice Guided by the CCR7 Chemokine Receptor. <i>International Journal of Molecular Sciences</i> , 2014, 15, 15304-15319.	1.8	2
89	Nanoparticles in the Development of Therapeutic Cancer Vaccines. <i>Pharmaceutical Nanotechnology</i> , 2014, 2, 2-22.	0.6	6
90	Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops. <i>Current Signal Transduction Therapy</i> , 2014, 8, 193-202.	0.3	57
91	Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. <i>OncoTargets and Therapy</i> , 2014, 7, 865.	1.0	17

#	ARTICLE	IF	CITATIONS
92	Human CD103 ⁺ dendritic cells promote the differentiation of Porphyromonas gingivalis heat shock protein peptide-specific regulatory T cells. Journal of Periodontal and Implant Science, 2014, 44, 235.	0.9	4
93	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
94	Live attenuated measles virus vaccine therapy for locally established malignant glioblastoma tumor cells. Oncolytic Virotherapy, 2014, 3, 57.	6.0	11
96	Synergistic effects of glycosylated chitosan with high-intensity focused ultrasound on suppression of metastases in a syngeneic breast tumor model. Cell Death and Disease, 2014, 5, e1178-e1178.	2.7	28
97	Oncolytic Poxviruses. Annual Review of Virology, 2014, 1, 191-214.	3.0	87
98	Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells. Oncoimmunology, 2014, 3, e28541.	2.1	12
99	Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death and Differentiation, 2014, 21, 15-25.	5.0	740
100	Cancer vaccines: What do we need to measure in clinical trials?. Human Vaccines and Immunotherapeutics, 2014, 10, 3236-3240.	1.4	10
101	Disruption of CD8+ Treg Activity Results in Expansion of T Follicular Helper Cells and Enhanced Antitumor Immunity. Cancer Immunology Research, 2014, 2, 207-216.	1.6	38
102	Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 902-915.	1.9	36
103	MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy. , 2014, 2, 32.		7
104	Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms. British Journal of Cancer, 2014, 110, 83-93.	2.9	54
105	Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene, 2014, 33, 5405-5414.	2.6	97
106	5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer Journal, 2014, 4, e197-e197.	2.8	67
107	The immune escape in melanoma: role of the impaired dendritic cell function. Expert Review of Clinical Immunology, 2014, 10, 1395-1404.	1.3	56
108	Immunologic biomarkers in prostate cancer. Human Vaccines and Immunotherapeutics, 2014, 10, 1244-1247.	1.4	3
109	Blockade of mTOR Signaling via Rapamycin Combined with Immunotherapy Augments Antiglioma Cytotoxic and Memory T-Cell Functions. Molecular Cancer Therapeutics, 2014, 13, 3024-3036.	1.9	48
110	Computer-Aided Targeting of the PI3K/Akt/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities. International Journal of Molecular Sciences, 2014, 15, 18856-18891.	1.8	63

#	ARTICLE	IF	CITATIONS
112	Enhancing Chemotherapy Efficacy in Pten -Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity. <i>Cell Reports</i> , 2014, 9, 75-89.	2.9	313
113	T lymphocytes targeting native receptors. <i>Immunological Reviews</i> , 2014, 257, 39-55.	2.8	34
114	Nano-Oncologicals. <i>Advances in Delivery Science and Technology</i> , 2014, , .	0.4	7
115	Assessment of MAGE-A Expression in Resected Nonâ€“Small Cell Lung Cancer in Relation to Clinicopathologic Features and Mutational Status of <i>EGFR</i> and <i>KRAS</i>. <i>Cancer Immunology Research</i> , 2014, 2, 943-948.	1.6	20
116	Advances in Anticancer Protein Delivery using Microâ€“Nanoparticles. <i>Particle and Particle Systems Characterization</i> , 2014, 31, 1204-1222.	1.2	30
117	Nanotechnology Approaches for Cancer Immunotherapy and Immunomodulation. <i>Advances in Delivery Science and Technology</i> , 2014, , 215-242.	0.4	4
118	Inactivation of <scp>MYC</scp> reverses tumorigenesis. <i>Journal of Internal Medicine</i> , 2014, 276, 52-60.	2.7	51
119	Combining Targeted Agents With Modern Radiotherapy in Soft Tissue Sarcomas. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju329-dju329.	3.0	26
120	Transcriptomic analysis of a transgenic zebrafish hepatocellular carcinoma model reveals a prominent role of immune responses in tumour progression and regression. <i>International Journal of Cancer</i> , 2014, 135, 1564-1573.	2.3	18
121	PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond. <i>Cancer Immunology Research</i> , 2014, 2, 1132-1141.	1.6	42
122	BRAF-targeted therapy alters the functions of intratumoral CD4+T cells to inhibit melanoma progression. <i>Oncimmunology</i> , 2014, 3, e29126.	2.1	5
123	Oncogene withdrawal engages the immune system to induce sustained cancer regression. , 2014, 2, 24.		19
124	Anti-cancer properties of gastropodan hemocyanins in murine model of colon carcinoma. <i>BMC Immunology</i> , 2014, 15, 34.	0.9	37
125	Taxanes in combination with biologic agents for ovarian and breast cancers. <i>Anti-Cancer Drugs</i> , 2014, 25, 536-554.	0.7	2
126	Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC. <i>Journal of Thoracic Oncology</i> , 2014, 9, 144-153.	0.5	83
127	Therapeutic Cancer Vaccines. <i>Advances in Cancer Research</i> , 2014, 121, 67-124.	1.9	68
128	Potential synergistic antiâ€“tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 2021-2031.	1.4	12
129	Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells. <i>Frontiers in Oncology</i> , 2014, 4, 270.	1.3	3

#	ARTICLE	IF	CITATIONS
130	Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. , 2014, 2, 7.		105
131	A personalized view on cancer immunotherapy. Cancer Letters, 2014, 352, 113-125.	3.2	63
132	Adenovirus-mediated CCL20/IL-15 gene transfer enhances antitumor immunity in mice. Immunobiology, 2014, 219, 475-481.	0.8	6
133	Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunology, Immunotherapy, 2014, 63, 29-36.	2.0	126
134	New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. Current Opinion in Immunology, 2014, 27, 16-25.	2.4	1,163
135	The stromal compartments in pancreatic cancer: Are there any therapeutic targets?. Cancer Letters, 2014, 343, 147-155.	3.2	155
136	Dendritic cells and cancer immunotherapy. Current Opinion in Immunology, 2014, 27, 26-32.	2.4	108
137	Targeting Survivin in Cancer: Novel Drug Development Approaches. BioDrugs, 2014, 28, 27-39.	2.2	70
138	Novel Bispecific Antibodies Increase $\gamma\delta$ T-Cell Cytotoxicity against Pancreatic Cancer Cells. Cancer Research, 2014, 74, 1349-1360.	0.4	133
139	Various ways to improve whole cancer cell vaccines. Expert Review of Vaccines, 2014, 13, 721-735.	2.0	39
140	Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells. Cancer Research, 2014, 74, 2663-2668.	0.4	123
141	Polymer-coated spherical mesoporous silica for pH-controlled delivery of insulin. Journal of Materials Chemistry B, 2014, 2, 616-619.	2.9	29
142	Mouse tumour models to guide drug development and identify resistance mechanisms. Journal of Pathology, 2014, 232, 103-111.	2.1	28
143	An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunologic Research, 2014, 58, 282-291.	1.3	18
144	USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses. Nature Immunology, 2014, 15, 562-570.	7.0	204
145	Smac mimetics and innate immune stimuli synergize to promote tumor death. Nature Biotechnology, 2014, 32, 182-190.	9.4	104
146	Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery. Chemical Society Reviews, 2014, 43, 444-472.	18.7	157
147	De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Medicine, 2014, 40, 41-49.	3.9	106

#	ARTICLE	IF	CITATIONS
148	Immune Modulation in Cancer with Antibodies. <i>Annual Review of Medicine</i> , 2014, 65, 185-202.	5.0	455
149	Gold nanoparticle mediated cancer immunotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 503-514.	1.7	187
150	Molecular mechanisms of ATP secretion during immunogenic cell death. <i>Cell Death and Differentiation</i> , 2014, 21, 79-91.	5.0	395
151	Genomic Sequencing for Cancer Diagnosis and Therapy. <i>Annual Review of Medicine</i> , 2014, 65, 33-48.	5.0	35
152	PI3K and cancer: lessons, challenges and opportunities. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 140-156.	21.5	1,398
153	The immune system and response to HER2-targeted treatment in breast cancer. <i>Lancet Oncology</i> , The, 2014, 15, e58-e68.	5.1	244
154	Development of anticancer drugs based on the hallmarks of tumor cells. <i>Tumor Biology</i> , 2014, 35, 3981-3995.	0.8	29
155	The folate receptor as a rational therapeutic target for personalized cancer treatment. <i>Drug Resistance Updates</i> , 2014, 17, 89-95.	6.5	301
156	Future Approaches in Immunotherapy. <i>Seminars in Oncology</i> , 2014, 41, S30-S40.	0.8	27
157	Reactive Species from Cold Atmospheric Plasma: Implications for Cancer Therapy. <i>Plasma Processes and Polymers</i> , 2014, 11, 1120-1127.	1.6	227
158	Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. <i>Oncogene</i> , 2014, 33, 5053-5064.	2.6	41
159	Sweeping lymph node micrometastases off their feet: an engineered model to evaluate natural killer cell mediated therapeutic intervention of circulating tumor cells that disseminate to the lymph nodes. <i>Lab on A Chip</i> , 2014, 14, 118-127.	3.1	19
160	Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects. <i>Clinical Cancer Research</i> , 2014, 20, 6258-6268.	3.2	88
162	Chemical biology approaches to target validation in cancer. <i>Current Opinion in Pharmacology</i> , 2014, 17, 87-100.	1.7	36
163	Hostile, Hypoxia-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists. <i>Cancer Immunology Research</i> , 2014, 2, 598-605.	1.6	180
164	Exploiting differential expression of the IL-7 receptor on memory T cells to modulate immune responses. <i>Cytokine and Growth Factor Reviews</i> , 2014, 25, 391-401.	3.2	31
165	Therapy: This time it's personal. <i>Nature</i> , 2014, 509, S52-S54.	13.7	10
166	Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes. <i>Cancer Immunology Research</i> , 2014, 2, 436-447.	1.6	165

#	ARTICLE	IF	CITATIONS
167	Development of U11-Functionalized Gold Nanoparticles for Selective Targeting of Urokinase Plasminogen Activator Receptor-Positive Breast Cancer Cells. <i>Bioconjugate Chemistry</i> , 2014, 25, 1381-1386.	1.8	19
168	Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1219-1228.	1.1	1
169	Gene Therapy: Charting a Future Course—Summary of a National Institutes of Health Workshop, April 12, 2013. <i>Human Gene Therapy</i> , 2014, 25, 488-497.	1.4	12
170	Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2014, 20, 5898-5907.	3.2	72
171	A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. , 2014, 2, 30.		27
172	Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. <i>Biotechnology Journal</i> , 2014, 9, 1104-1114.	1.8	43
173	Synthesis of Multifunctional Fe ₃ O ₄ –CdSe/ZnS Nanoclusters Coated with Lipid A toward Dendritic Cell-Based Immunotherapy. <i>ACS Applied Materials & Interfaces</i> , 2014, 6, 5297-5307.	4.0	18
174	Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 737-745.	2.7	10
175	Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 927-961.	1.3	33
176	Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines. <i>Cytotherapy</i> , 2014, 16, 427-439.	0.3	27
177	Engineering vaccines and niches for immune modulation. <i>Acta Biomaterialia</i> , 2014, 10, 1728-1740.	4.1	42
178	Interferon- γ -secreting mesenchymal stem cells exert potent antitumor effect in vivo. <i>Oncogene</i> , 2014, 33, 5047-5052.	2.6	43
179	Viruses for Tumor Therapy. <i>Cell Host and Microbe</i> , 2014, 15, 260-265.	5.1	131
180	The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. <i>Biomaterials</i> , 2014, 35, 5491-5504.	5.7	108
181	Current Advances in Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2014, , .	0.8	14
182	Synergistic Enhancement of Lung Cancer Therapy Through Nanocarrier-Mediated Sequential Delivery of Superantigen and Tyrosin Kinase Inhibitor. <i>Advanced Functional Materials</i> , 2014, 24, 5482-5492.	7.8	17
183	NKT Cell Responses to B Cell Lymphoma. <i>Medical Sciences (Basel, Switzerland)</i> , 2014, 2, 82-97.	1.3	15
184	Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review). <i>International Journal of Oncology</i> , 2014, 45, 929-949.	1.4	34

#	ARTICLE	IF	CITATIONS
186	Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3' untranslated region of TRIT1. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14009.	2.0	2
187	The potential of genome-wide analyses to improve non-small-cell lung cancer care. <i>Lung Cancer Management</i> , 2014, 3, 383-396.	1.5	0
188	Expression of the mi R 302/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes. <i>International Journal of Cancer</i> , 2015, 137, 2296-2309.	2.3	34
189	Composite peptide-based vaccines for cancer immunotherapy (Review). <i>International Journal of Molecular Medicine</i> , 2015, 35, 17-23.	1.8	16
190	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2015, 5, 13110.	1.6	310
194	Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC following Chemotherapy. <i>Clinical Medicine Insights: Oncology</i> , 2015, 9, CMO.S23252.	0.6	27
195	Dabrafenib and its use in the treatment of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 199-208.	0.1	21
196	Smart CARs engineered for cancer immunotherapy. <i>Current Opinion in Oncology</i> , 2015, 27, 466-474.	1.1	63
197	Classification of clinical outcomes using high-throughput informatics: Part 1 "nonparametric method reviews. <i>Model Assisted Statistics and Applications</i> , 2015, 10, 3-23.	0.2	8
198	Cancer stem cell plasticity and tumor hierarchy. <i>World Journal of Stem Cells</i> , 2015, 7, 27.	1.3	202
200	Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2015, 8, 145.	0.4	15
201	Review Computational characterisation of cancer molecular profiles derived using next generation sequencing. <i>Wspolczesna Onkologia</i> , 2015, 1A, 78-91.	0.7	4
202	Antibody opsonization of tumor cell membranes using hapten-PEG-lipid conjugates. <i>Journal of Biomedical Engineering and Informatics</i> , 2015, 2, 1.	0.2	0
203	Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. <i>Vaccines</i> , 2015, 3, 597-619.	2.1	46
204	Primary Human Blood Dendritic Cells for Cancer Immunotherapy"Tailoring the Immune Response by Dendritic Cell Maturation. <i>Biomedicines</i> , 2015, 3, 282-303.	1.4	22
205	Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 271.	2.2	36
206	Present and Future of Allogeneic Natural Killer Cell Therapy. <i>Frontiers in Immunology</i> , 2015, 6, 286.	2.2	70
207	Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs. <i>Frontiers in Immunology</i> , 2015, 6, 501.	2.2	33

#	ARTICLE	IF	CITATIONS
208	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 516.	2.2	79
209	Immunosuppression in Early Postnatal Days Induces Persistent and Allergen-Specific Immune Tolerance to Asthma in Adult Mice. <i>PLoS ONE</i> , 2015, 10, e0122990.	1.1	0
210	Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial. <i>PLoS ONE</i> , 2015, 10, e0124612.	1.1	20
211	Therapeutic strategy for cancer immunotherapy in head and neck cancer. <i>Advances in Cellular and Molecular Otolaryngology</i> , 2015, 3, 27690.	0.4	5
212	Cisplatin Loaded Hyaluronic Acid Modified TiO ₂ Nanoparticles for Neoadjuvant Chemotherapy of Ovarian Cancer. <i>Journal of Nanomaterials</i> , 2015, 2015, 1-8.	1.5	21
213	Comment on "5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity". <i>Mediators of Inflammation</i> , 2015, 2015, 1-3.	1.4	0
214	Challenging the Treatment Paradigm for Advanced Renal Cell Carcinoma: A Review of Systemic and Localized Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e239-e247.	1.8	9
216	Immunoediting, Immunosurveillance, Tumor-induced Immunosuppression and Immuno-resistance, Immunomodulation, Immunotherapy, and Immunonutrition in Personalized and Precision Cancer Medicine. , 0, , .		1
217	Principles of Cancer Immunobiology and Immunotherapy of Solid Tumors. , 0, , .		4
218	Improved Efficacy of a Dendritic Cell-Based Vaccine against a Murine Model of Colon Cancer: The Helper Protein Effect. <i>Cancer Research and Treatment</i> , 2015, 47, 518-526.	1.3	13
219	PD-L1 Blockade for Cancer Treatment: MEDI4736. <i>Seminars in Oncology</i> , 2015, 42, 474-483.	0.8	86
220	Transcriptional changes associated with resistance to inhibitors of epidermal growth factor receptor revealed using metaanalysis. <i>BMC Cancer</i> , 2015, 15, 369.	1.1	4
221	Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists. <i>Science Advances</i> , 2015, 1, .	4.7	72
222	<i>Fusobacterium nucleatum</i> and T Cells in Colorectal Carcinoma. <i>JAMA Oncology</i> , 2015, 1, 653.	3.4	498
223	Complete destruction of deep-tissue buried tumors via combination of gene silencing and gold nanoechinus-mediated photodynamic therapy. <i>Biomaterials</i> , 2015, 62, 13-23.	5.7	45
224	6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1033-1046.	2.0	56
225	IFN β Induces DNA Methylation-Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 795-805.	1.6	44
226	The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1273-1275.	1.9	10

#	ARTICLE	IF	CITATIONS
227	Affective Science Perspectives on Cancer Control. <i>Perspectives on Psychological Science</i> , 2015, 10, 328-345.	5.2	54
229	Combinations Therapies. <i>Progress in Tumor Research</i> , 2015, 42, 79-94.	0.1	0
230	An endoscope with integrated transparent bioelectronics and theranostic nanoparticles for colon cancer treatment. <i>Nature Communications</i> , 2015, 6, 10059.	5.8	159
231	Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1487-1494.	2.0	51
232	T Cell Fate in the Tumor Microenvironment. <i>Cancer Drug Discovery and Development</i> , 2015, , 53-74.	0.2	0
233	A novel anticancer diarylurea derivative HL-40 as a multi-kinases inhibitor with good pharmacokinetics in Wistar rats. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 255-259.	2.5	6
234	Envisioning the Application of Systems Biology in Cancer Immunology. , 2015, , 429-449.		3
235	Molecular docking and dynamic simulation studies evidenced plausible immunotherapeutic anticancer property by Withaferin A targeting indoleamine 2,3-dioxygenase. <i>Journal of Biomolecular Structure and Dynamics</i> , 2015, 33, 2695-2709.	2.0	51
236	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolimmunology</i> , 2015, 4, e974411.	2.1	97
237	SOCS3 Deficiency in Myeloid Cells Promotes Tumor Development: Involvement of STAT3 Activation and Myeloid-Derived Suppressor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 727-740.	1.6	54
238	InCVAX â€œ A novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity. <i>Cancer Letters</i> , 2015, 359, 169-177.	3.2	62
239	Combining Immunotherapy and Radiation for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 1-9.	0.9	41
240	Prognosis of neutropenic patients admitted to the intensive care unit. <i>Intensive Care Medicine</i> , 2015, 41, 296-303.	3.9	67
241	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015, 25, 208-224.	5.7	143
242	Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 69-83.	1.1	13
243	Molecular Basis for Treating Cutaneous Melanoma. , 2015, , 591-600.e3.		0
244	Current trends in using polymer coated gold nanoparticles for cancer therapy. <i>International Journal of Pharmaceutics</i> , 2015, 484, 252-267.	2.6	215
245	Current understanding of synergistic interplay of chitosan nanoparticles and anticancer drugs: merits and challenges. <i>Applied Microbiology and Biotechnology</i> , 2015, 99, 2055-2064.	1.7	26

#	ARTICLE	IF	CITATIONS
246	Can the chemotherapeutic agents perform anticancer activity through miRNA expression regulation? Proposing a new hypothesis. <i>Protoplasma</i> , 2015, 252, 1603-1610.	1.0	7
247	Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 461-477.	1.3	31
248	Big opportunities for small molecules in immuno-oncology. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 603-622.	21.5	369
250	Clinical translation for endometrial cancer stem cells hypothesis. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 401-416.	2.7	31
251	Tumor Immunotherapy of Esophageal and Gastric Cancers. , 2015, , 185-197.		0
252	Antigen-specific T cell therapies for cancer: Figure 1.. <i>Human Molecular Genetics</i> , 2015, 24, R67-R73.	1.4	32
253	pH-sensitive polymer-liposome-based antigen delivery systems potentiated with interferon- β gene lipoplex for efficient cancer immunotherapy. <i>Biomaterials</i> , 2015, 67, 214-224.	5.7	83
254	Engineering New Approaches to Cancer Vaccines. <i>Cancer Immunology Research</i> , 2015, 3, 836-843.	1.6	50
255	The immun checkpoints in modern oncology: the next 15 years. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 917-921.	1.4	24
256	Identifying genes that mediate anthracycline toxicity in immune cells. <i>Frontiers in Pharmacology</i> , 2015, 6, 62.	1.6	4
258	OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. <i>Frontiers in Oncology</i> , 2015, 5, 34.	1.3	193
259	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. <i>Oncologist</i> , 2015, 20, 812-822.	1.9	198
260	Preparation of adenovirus-templated gold nanoshells and a study of their photothermal therapy efficacy. <i>New Journal of Chemistry</i> , 2015, 39, 3608-3614.	1.4	12
261	Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges. <i>Frontiers in Immunology</i> , 2015, 6, 12.	2.2	89
262	Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. <i>Cancer Biology and Therapy</i> , 2015, 16, 662-670.	1.5	27
263	A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1368-1386.	1.4	16
264	Portrait of inflammatory response to ionizing radiation treatment. <i>Journal of Inflammation</i> , 2015, 12, 14.	1.5	208
265	Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer. <i>Journal of Translational Medicine</i> , 2015, 13, 78.	1.8	31

#	ARTICLE	IF	CITATIONS
266	Inflammation and Immunity in Cancer. , 2015, , .		1
267	Haematological malignancies: at the forefront of immunotherapeutic innovation. Nature Reviews Cancer, 2015, 15, 201-215.	12.8	63
268	Cancer Nanotherapeutics in Clinical Trials. Cancer Treatment and Research, 2015, 166, 293-322.	0.2	34
269	Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer. Cancer Treatment and Research, 2015, , .	0.2	25
270	Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 743-756.	1.5	16
271	Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Oncology, 2015, 27, 108-117.	1.1	26
272	An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects. Advanced Healthcare Materials, 2015, 4, 1034-1042.	3.9	38
273	Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends in Immunology, 2015, 36, 198-216.	2.9	121
274	Bidirectional interactions of NK cells and dendritic cells in immunotherapy: current and future perspective. Immunotherapy, 2015, 7, 301-308.	1.0	19
275	Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases. Clinical Immunology, 2015, 160, 46-58.	1.4	148
276	Immune-checkpoint blockade: the springboard for immuno-combination therapy. Gene Therapy, 2015, 22, 849-850.	2.3	3
277	Genomic spectra of biliary tract cancer. Nature Genetics, 2015, 47, 1003-1010.	9.4	907
278	Complementary IMAC enrichment methods for HLA-associated phosphopeptide identification by mass spectrometry. Nature Protocols, 2015, 10, 1308-1318.	5.5	67
279	Pharmacologic Management of Advanced Cervical Cancer: Antiangiogenesis Therapy and Immunotherapeutic Considerations. Drugs, 2015, 75, 1853-1865.	4.9	11
280	The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncolmmunology, 2015, 4, e1042198.	2.1	36
281	Polypharmacology Shakes Hands with Complex Aetiopathology. Trends in Pharmacological Sciences, 2015, 36, 802-821.	4.0	29
282	Small bowel sarcoma: Tumor biology and advances in therapeutics. Surgical Oncology, 2015, 24, 136-144.	0.8	5
283	Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives. European Journal of Medicinal Chemistry, 2015, 101, 754-768.	2.6	31

#	ARTICLE	IF	CITATIONS
285	Efficacy of a Cancer Vaccine against <i>ALK</i> -Rearranged Lung Tumors. <i>Cancer Immunology Research</i> , 2015, 3, 1333-1343.	1.6	42
286	Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. <i>Carcinogenesis</i> , 2015, 36, S111-S127.	1.3	43
287	Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. <i>Nature Medicine</i> , 2015, 21, 1010-1017.	15.2	131
288	Personalizing chemotherapy dosing using pharmacological methods. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 879-896.	1.1	21
289	Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response. <i>OncImmunology</i> , 2015, 4, e998469.	2.1	41
290	Sensitive Multiplexed Quantitative Analysis of Autoantibodies to Cancer Antigens with Chemically <i>S</i> -Cationized Full-Length and Water-Soluble Denatured Proteins. <i>Bioconjugate Chemistry</i> , 2015, 26, 2076-2084.	1.8	9
291	Engineering opportunities in cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14467-14472.	3.3	111
292	CAR T cell immunotherapy: The path from the byroad to the freeway?. <i>Molecular Oncology</i> , 2015, 9, 1994-2018.	2.1	43
293	Natural killer cells: The journey from puzzles in biology to treatment of cancer. <i>Cancer Letters</i> , 2015, 357, 454-467.	3.2	42
294	Immunoprevention of Human Papillomavirus-Associated Malignancies. <i>Cancer Prevention Research</i> , 2015, 8, 95-104.	0.7	25
295	Ru(II) dyads derived from π -oligothiophenes: A new class of potent and versatile photosensitizers for PDT. <i>Coordination Chemistry Reviews</i> , 2015, 282-283, 127-138.	9.5	226
296	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. <i>International Immunology</i> , 2015, 27, 39-46.	1.8	286
297	Epirubicin-Loaded Superparamagnetic Iron-Oxide Nanoparticles for Transdermal Delivery: Cancer Therapy by Circumventing the Skin Barrier. <i>Small</i> , 2015, 11, 239-247.	5.2	73
298	T cell-based targeted immunotherapies for patients with multiple myeloma. <i>International Journal of Cancer</i> , 2015, 136, 1751-1768.	2.3	10
299	Combining Immunotherapies with Standard Therapies in the Treatment of Cancer. , 2016, , 569-580.		0
300	In Silico Approach to Find an Optimal Strategy in Selective Targeting of Cancer Cells. <i>Journal of Computer Science and Systems Biology</i> , 2016, 9, .	0.0	1
301	Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. <i>Oncotarget</i> , 2016, 7, 75407-75424.	0.8	66
302	Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application. , 2016, , 813-869.		5

#	ARTICLE	IF	CITATIONS
303	Identification of candidate anti-cancer molecular mechanisms of Compound Kushen Injection using functional genomics. <i>Oncotarget</i> , 2016, 7, 66003-66019.	0.8	87
304	TGF- β 2 and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. <i>JCI Insight</i> , 2016, 1, e85974.	2.3	91
305	Nanodelivery of Anticancer Agents in Melanoma. , 2016, , 189-201.		2
306	Enhanced Anti-Tumor Efficacy through a Combination of Integrin α 6 β 1-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition. <i>Theranostics</i> , 2016, 6, 627-637.	4.6	92
307	Systemic Chemotherapy in Advanced Pancreatic Cancer. <i>Gut and Liver</i> , 2016, 10, 340-7.	1.4	57
308	Systems Perturbation Analysis of a Large-Scale Signal Transduction Model Reveals Potentially Influential Candidates for Cancer Therapeutics. <i>Frontiers in Bioengineering and Biotechnology</i> , 2016, 4, 10.	2.0	29
309	Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment. <i>Vaccines</i> , 2016, 4, 41.	2.1	44
310	Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma. <i>Journal of Immunology Research</i> , 2016, 2016, 1-10.	0.9	14
311	Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report. <i>Frontiers in Oncology</i> , 2016, 6, 250.	1.3	17
313	Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5101-5116.	1.0	27
314	High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-κB signaling pathway in non-small cell lung cancer cells. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6511-6518.	1.0	13
315	Folate-modified Chitosan Nanoparticles Containing the IP-10 Gene Enhance Melanoma-specific Cytotoxic CD8 ⁺ CD28 ⁺ T Lymphocyte Responses. <i>Theranostics</i> , 2016, 6, 752-761.	4.6	40
316	Stem Cell Membraneâ€Coated Nanogels for Highly Efficient In Vivo Tumor Targeted Drug Delivery. <i>Small</i> , 2016, 12, 4056-4062.	5.2	271
317	Autophagy and Immune Senescence. <i>Trends in Molecular Medicine</i> , 2016, 22, 671-686.	3.5	67
318	Synergistic antitumor responses by combined <sc>GTR</sc> activation and sunitinib in metastatic renal cell carcinoma. <i>International Journal of Cancer</i> , 2016, 138, 451-462.	2.3	19
319	Epigenetic Pharmacology. , 2016, , 1-25.		0
320	'Trained immunity: consequences for lymphoid malignancies. <i>Haematologica</i> , 2016, 101, 1460-1468.	1.7	21
321	Photodynamic Therapy Mediated by Nontoxic Coreâ€Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. <i>Journal of the American Chemical Society</i> , 2016, 138, 16686-16695.	6.6	384

#	ARTICLE	IF	CITATIONS
322	Model-based genotype-phenotype mapping used to investigate gene signatures of immune sensitivity and resistance in melanoma micrometastasis. <i>Scientific Reports</i> , 2016, 6, 24967.	1.6	19
323	Integrating precision cancer medicine into healthcare—policy, practice, and research challenges. <i>Genome Medicine</i> , 2016, 8, 108.	3.6	46
324	A light-controlled switch after dual targeting of proliferating tumor cells via the membrane receptor EGFR and the nuclear protein Ki-67. <i>Scientific Reports</i> , 2016, 6, 27032.	1.6	13
325	Targeting the Microenvironment in Advanced Colorectal Cancer. <i>Trends in Cancer</i> , 2016, 2, 495-504.	3.8	80
326	Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study. <i>Scientific Reports</i> , 2016, 6, 38407.	1.6	18
327	Intratumoral Immunization by p19Arf and Interferon- γ Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma. <i>Translational Oncology</i> , 2016, 9, 565-574.	1.7	21
328	Immunological off-target effects of imatinib. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 431-446.	12.5	120
329	Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 413-426.	2.7	44
330	Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies. <i>Acta Oncologica</i> , 2016, 55, 930-932.	0.8	19
331	Nanomedicine. <i>Advances in Delivery Science and Technology</i> , 2016, , .	0.4	6
332	Malignant melanoma—The cradle of anti-neoplastic immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 25-54.	2.0	33
333	Beyond monotherapy: Integrating immunotherapy into current treatment regimens. <i>Journal of Thoracic Oncology</i> , 2016, 11, S8-S9.	0.5	0
334	Photonics immunotherapy — A novel strategy for cancer treatment. <i>Journal of Innovative Optical Health Sciences</i> , 2016, 09, 1630001.	0.5	22
335	Targeting K-Ras cancers. <i>Journal of Thoracic Oncology</i> , 2016, 11, S9-S10.	0.5	0
336	The Role of Surgical Pathology in Guiding Cancer Immunotherapy. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 313-341.	9.6	15
337	Infiltration of lymphocyte subpopulations into cancer microtissues as a tool for the exploration of immunomodulatory agents and biomarkers. <i>Immunobiology</i> , 2016, 221, 604-617.	0.8	7
338	One-pot construction of boronate ester based pH-responsive micelle for combined cancer therapy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 143, 285-292.	2.5	13
339	Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers. <i>Cancer Immunology Research</i> , 2016, 4, 611-620.	1.6	73

#	ARTICLE	IF	CITATIONS
340	From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. <i>Drug Discovery Today</i> , 2016, 21, 1027-1036.	3.2	137
341	Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. <i>Cancer Cell</i> , 2016, 29, 587-601.	7.7	375
342	Emerging nanotechnologies for cancer immunotherapy. <i>Experimental Biology and Medicine</i> , 2016, 241, 1116-1126.	1.1	26
343	Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 737-749.	1.5	24
344	Biology and treatment of BRAF mutant metastatic melanoma. <i>Melanoma Management</i> , 2016, 3, 33-45.	0.1	28
345	Immunotherapy in head and neck cancer: Harnessing profit on a system disruption. <i>Oral Oncology</i> , 2016, 62, 153-162.	0.8	8
346	Realism and pragmatism in developing an effective chimeric antigen receptor T-cell product for solid cancers. <i>Cytotherapy</i> , 2016, 18, 1382-1392.	0.3	8
347	Hypoxia and antitumor CD8 ⁺ T cells: An incompatible alliance?. <i>Onc Immunology</i> , 2016, 5, e1232236.	2.1	61
348	Mouse models in oncoimmunology. <i>Nature Reviews Cancer</i> , 2016, 16, 759-773.	12.8	267
349	Therapeutic efficacy of an anti-PD-L1 antibody based immunocytokine in a metastatic mouse model of colorectal cancer. <i>Biochemical and Biophysical Research Communications</i> , 2016, 480, 160-165.	1.0	12
350	Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 431-440.	1.0	7
351	Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy. <i>Chemical Society Reviews</i> , 2016, 45, 6597-6626.	18.7	1,483
352	Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy. <i>ACS Nano</i> , 2016, 10, 9227-9242.	7.3	36
353	Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition. <i>Oncology Reports</i> , 2016, 36, 271-278.	1.2	135
354	Genomic and Transcriptomic Approaches to Study Cancer in Small Aquarium Fish Models. <i>Advances in Genetics</i> , 2016, 95, 31-63.	0.8	1
355	Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues. <i>Immunology</i> , 2016, 147, 141-151.	2.0	140
356	EZH2 as a mediator of treatment resistance in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 500-507.	1.5	37
357	Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC). <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 243-254.	1.0	5

#	ARTICLE	IF	CITATIONS
358	Precision glycoalyx editing as a strategy for cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10304-10309.	3.3	328
360	Novel Approaches to Apoptosis-Inducing Therapies. Advances in Experimental Medicine and Biology, 2016, 930, 173-204.	0.8	17
361	Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. Radiotherapy and Oncology, 2016, 120, 185-194.	0.3	99
362	Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. Cancer Medicine, 2016, 5, 1810-1820.	1.3	46
363	Bioengineered and biohybrid bacteria-based systems for drug delivery. Advanced Drug Delivery Reviews, 2016, 106, 27-44.	6.6	262
364	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood, 2016, 127, 3225-3236.	0.6	244
365	M2 polarization of murine peritoneal macrophages induces regulatory cytokine production and suppresses T cell proliferation. Immunology, 2016, 149, 320-328.	2.0	78
366	Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients. Pancreatology, 2016, 16, 1069-1079.	0.5	28
367	Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell, 2016, 30, 324-336.	7.7	717
368	Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. Expert Opinion on Biological Therapy, 2016, 16, 1209-1223.	1.4	18
369	Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. Npj Genomic Medicine, 2016, 1, .	1.7	68
370	Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. Oncologist, 2016, 21, 1250-1259.	1.9	85
371	Therapeutics Targeting FGF Signaling Network in Human Diseases. Trends in Pharmacological Sciences, 2016, 37, 1081-1096.	4.0	172
372	IGF-1/GH axis enhances losartan treatment in Lama2-related muscular dystrophy. Human Molecular Genetics, 2016, 25, ddw291.	1.4	21
373	An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nature Communications, 2016, 7, 13443.	5.8	156
374	Immunotherapy for Renal Cancer: Sequencing and Combinations. European Urology Focus, 2016, 2, 582-588.	1.6	5
375	Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2016, , .	0.8	6
376	Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives. Journal of Controlled Release, 2016, 240, 489-503.	4.8	258

#	ARTICLE	IF	CITATIONS
377	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016, 4, 679-687.	1.6	81
378	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2016, 13, 420-431.	1.9	78
379	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. <i>Seminars in Oncology</i> , 2016, 43, 501-513.	0.8	10
380	Combinatorial approach to cancer immunotherapy: strength in numbers. <i>Journal of Leukocyte Biology</i> , 2016, 100, 275-290.	1.5	90
381	Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach. <i>Cancer Letters</i> , 2016, 379, 32-38.	3.2	41
382	Adoptive Cellular Therapy (ACT) for Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2016, 909, 169-239.	0.8	14
383	Nuclear Phosphoproteomic Screen Uncovers ACLY as Mediator of IL-2-induced Proliferation of CD4+ T lymphocytes. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 2076-2092.	2.5	40
384	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. , 2016, , 1-39.		0
385	Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 663-675.	2.0	12
386	Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress. <i>Future Oncology</i> , 2016, 12, 355-372.	1.1	16
387	Immune Checkpoint inhibitors: An introduction to the next generation cancer immunotherapy. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 157-169.	1.0	102
388	Polymer-Based DNA Delivery Systems for Cancer Immunotherapy. <i>Advances in Delivery Science and Technology</i> , 2016, , 221-244.	0.4	1
389	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. , 2016, 166, 9-29.		33
390	Novel biotin-functionalized lipidic nanocarriers for encapsulating BpT and Bp4eT iron chelators: evaluation of potential anti-tumour efficacy by in vitro, in vivo and pharmacokinetic studies in A549 mice models. <i>RSC Advances</i> , 2016, 6, 61585-61598.	1.7	7
391	Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. <i>Nature Communications</i> , 2016, 7, 10499.	5.8	124
392	Biomaterial-based regional chemotherapy: Local anticancer drug delivery to enhance chemotherapy and minimize its side-effects. <i>Materials Science and Engineering C</i> , 2016, 62, 927-942.	3.8	142
393	Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. <i>Cancer Treatment Reviews</i> , 2016, 43, 113-123.	3.4	9
394	PEG- b -PLA micelles and PLGA- b -PEG- b -PLGA sol-gels for drug delivery. <i>Journal of Controlled Release</i> , 2016, 240, 191-201.	4.8	131

#	ARTICLE	IF	CITATIONS
395	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 57-75.	1.5	46
396	Targeting tumor-associated immune suppression with selective protein kinase A type I (PKAI) inhibitors may enhance cancer immunotherapy. Medical Hypotheses, 2016, 86, 56-59.	0.8	5
397	Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example. Clinical Cancer Research, 2016, 22, 1318-1324.	3.2	108
398	A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice. Oncoimmunology, 2016, 5, e1147641.	2.1	40
399	Design of pH-sensitive polymer-modified liposomes for antigen delivery and their application in cancer immunotherapy. Polymer Journal, 2016, 48, 761-771.	1.3	22
400	Checkpoint inhibitors in Hodgkin's lymphoma. European Journal of Haematology, 2016, 96, 335-343.	1.1	14
401	Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection. Forum for Health Economics and Policy, 2016, 19, 141-156.	0.2	5
402	RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment?. Materials Today, 2016, 19, 29-43.	8.3	31
403	Thiolated carboxymethyl dextran as a nanocarrier for colon delivery of hSET1 antisense: In vitro stability and efficiency study. Materials Science and Engineering C, 2016, 62, 771-778.	3.8	28
404	Microfluidics: A New Tool for Modeling Cancer-Immune Interactions. Trends in Cancer, 2016, 2, 6-19.	3.8	163
405	The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Science Translational Medicine, 2016, 8, 327ra26.	5.8	360
406	Coinhibitory Pathways in Immunotherapy for Cancer. Annual Review of Immunology, 2016, 34, 539-573.	9.5	718
407	Nanoscale characterization illustrates the cisplatin-mediated biomechanical changes of B16-F10 melanoma cells. Physical Chemistry Chemical Physics, 2016, 18, 7124-7131.	1.3	17
408	Development of immuno-oncology drugs " from CTLA4 to PD1 to the next generations. Nature Reviews Drug Discovery, 2016, 15, 235-247.	21.5	503
409	Advances in Therapeutic Cancer Vaccines. Advances in Immunology, 2016, 130, 191-249.	1.1	88
410	Self-adjuvanted hyaluronate " antigenic peptide conjugate for transdermal treatment of muscular dystrophy. Biomaterials, 2016, 81, 93-103.	5.7	21
411	Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Annals of Oncology, 2016, 27, 409-416.	0.6	597
412	Metal based nanoparticles as cancer antigen delivery vehicles for macrophage based antitumor vaccine. Vaccine, 2016, 34, 957-967.	1.7	30

#	ARTICLE	IF	CITATIONS
413	Emerging drugs for the treatment of sepsis. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 27-37.	1.0	24
414	Immunosuppressive cells in tumor immune escape and metastasis. <i>Journal of Molecular Medicine</i> , 2016, 94, 509-522.	1.7	270
415	<i>Systems Immunology</i> . , 2016, , 3-44.		0
416	Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. <i>Neuro-Oncology</i> , 2016, 18, 518-527.	0.6	57
417	The role of stearyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma. <i>Tumor Biology</i> , 2016, 37, 479-489.	0.8	12
418	MicroRNA <i>MIR21</i> and T Cells in Colorectal Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 33-40.	1.6	29
419	Combine and conquer: challenges for targeted therapy combinations in early phase trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 57-66.	12.5	239
420	Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	263
421	Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E970-E979.	3.3	172
422	Combating Established Mouse Glioblastoma through Nicotinylated Liposomes Mediated Targeted Chemotherapy in Combination with Dendritic Cell Based Genetic Immunization. <i>Advanced Biology</i> , 2017, 1, e1600009.	3.0	15
423	Novel Triazole-Piperazine Hybrid Molecules Induce Apoptosis via Activation of the Mitochondrial Pathway and Exhibit Antitumor Efficacy in Osteosarcoma Xenograft Nude Mice Model. <i>ACS Chemical Biology</i> , 2017, 12, 753-768.	1.6	22
424	Hydrogel microarray for detection of polymorphisms in the UGT1A1, DPYD, GSTP1 and ABCB1 genes. <i>Cancer Biomarkers</i> , 2017, 18, 265-272.	0.8	1
425	Isoimperatorin induces apoptosis of the SGC-7901 human gastric cancer cell line via the mitochondria-mediated pathway. <i>Oncology Letters</i> , 2017, 13, 518-524.	0.8	35
426	The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. <i>Nature Communications</i> , 2017, 8, 14638.	5.8	52
427	EGFR TKI combination with immunotherapy in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 465-469.	1.0	156
428	Making Targeted Therapy Compatible with Checkpoint Immunotherapy. <i>Trends in Biotechnology</i> , 2017, 35, 582-584.	4.9	1
429	Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies. <i>Cancer Research</i> , 2017, 77, 2686-2698.	0.4	77
430	Novel biotechnology approaches in colorectal cancer diagnosis and therapy. <i>Biotechnology Letters</i> , 2017, 39, 785-803.	1.1	18

#	ARTICLE	IF	CITATIONS
431	Immune modulation by dendritic-cell-based cancer vaccines. <i>Journal of Biosciences</i> , 2017, 42, 161-173.	0.5	15
432	Location of tumor affects local and distant immune cell type and number. <i>Immunity, Inflammation and Disease</i> , 2017, 5, 85-94.	1.3	14
433	The expanding role of immunotherapy. <i>Cancer Treatment Reviews</i> , 2017, 54, 74-86.	3.4	100
434	Adjuvant combination therapy with gemcitabine and autologous \hat{I}^{31} T-cell transfer in patients with curatively resected pancreatic cancer. <i>Cytotherapy</i> , 2017, 19, 473-485.	0.3	49
435	Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. <i>Angiogenesis</i> , 2017, 20, 205-215.	3.7	59
437	IFN \hat{I}^3 enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells. <i>International Immunopharmacology</i> , 2017, 47, 159-165.	1.7	20
438	Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy. <i>Frontiers of Chemical Science and Engineering</i> , 2017, 11, 676-684.	2.3	9
439	<i>Mammea longifolia</i> Planch. and Triana Fruit Extract Induces Cell Death in the Human Colon Cancer Cell Line, SW480, via Mitochondria-Related Apoptosis and Activation of p53. <i>Journal of Medicinal Food</i> , 2017, 20, 485-490.	0.8	8
440	Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. <i>Cancer Immunology Research</i> , 2017, 5, 446-454.	1.6	56
441	Combined delivery of a TGF- \hat{I}^2 inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy. <i>Acta Biomaterialia</i> , 2017, 61, 114-123.	4.1	29
442	Efficacy and safety of osimertinib in a Japanese compassionate use program. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 625-629.	0.6	12
443	Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management. <i>Cancer Research</i> , 2017, 77, 3666-3671.	0.4	93
444	The Immune Response to Implanted Materials and Devices. , 2017, , .		17
445	Self-Assembled Nano-immunostimulant for Synergistic Immune Activation. <i>ChemBioChem</i> , 2017, 18, 1721-1729.	1.3	15
446	Fabrication of gold nanocages and nanoshells using lanreotide acetate and a comparison study of their photothermal antitumor therapy. <i>Journal of Materials Chemistry B</i> , 2017, 5, 5641-5647.	2.9	13
447	Molecular Communication and Nanonetwork for Targeted Drug Delivery: A Survey. <i>IEEE Communications Surveys and Tutorials</i> , 2017, 19, 3046-3096.	24.8	127
448	DNA Damage and Repair Biomarkers of Immunotherapy Response. <i>Cancer Discovery</i> , 2017, 7, 675-693.	7.7	519
449	The combination of NK and CD8+ T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells. <i>Cellular Immunology</i> , 2017, 318, 35-41.	1.4	22

#	ARTICLE	IF	CITATIONS
450	Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. <i>Drugs</i> , 2017, 77, 1091-1103.	4.9	116
451	The microbiome and hepatobiliary-pancreatic cancers. <i>Cancer Letters</i> , 2017, 402, 9-15.	3.2	105
452	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017, 70, 34-42.	0.8	38
453	Modelling the spatiotemporal dynamics of chemovirotherapy cancer treatment. <i>Journal of Biological Dynamics</i> , 2017, 11, 244-274.	0.8	35
454	Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy. <i>Nature Communications</i> , 2017, 8, 15327.	5.8	61
455	Immunological characterization of a rigid I \pm -Tn mimetic on murine iNKT and human NK cells. <i>Glycoconjugate Journal</i> , 2017, 34, 553-562.	1.4	4
456	The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 1614-1626.	1.3	28
457	Novel lipoproteoplex delivers Keap1 siRNA based gene therapy to accelerate diabetic wound healing. <i>Biomaterials</i> , 2017, 132, 1-15.	5.7	105
458	Comprehensive insight into the binding of sunitinib, a multi-targeted anticancer drug to human serum albumin. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2017, 181, 254-263.	2.0	25
459	Targeted Chemo-Photodynamic Combination Platform Based on the DOX Prodrug Nanoparticles for Enhanced Cancer Therapy. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 13016-13028.	4.0	123
460	Smart NIR linear and nonlinear optical nanomaterials for cancer theranostics: Prospects in photomedicine. <i>Progress in Materials Science</i> , 2017, 88, 89-135.	16.0	84
461	Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer. <i>ACS Nano</i> , 2017, 11, 4463-4474.	7.3	583
462	Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion—A New Role for the AXL Receptor Tyrosine Kinase. <i>Clinical Cancer Research</i> , 2017, 23, 2928-2933.	3.2	59
463	Myeloid-derived suppressor cells and myeloid regulatory cells in cancer and autoimmune disorders. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 378-388.	0.8	14
464	Inhibition of protein kinases by anticancer DNA intercalator, 4-butylaminopyrimido[4,5]thieno(2,3-b)pyridine. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1000-1010.	5.7	104
465	Intrahepatic cholangiocarcinoma: current management and emerging therapies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 439-449.	1.4	58
466	CORR Insights: Can We Estimate Short- and Intermediate-term Survival in Patients Undergoing Surgery for Metastatic Bone Disease?. <i>Clinical Orthopaedics and Related Research</i> , 2017, 475, 1262-1264.	0.7	0
467	Detection of aberrant protein phosphorylation in cancer using direct gold-protein affinity interactions. <i>Biosensors and Bioelectronics</i> , 2017, 91, 8-14.	5.3	15

#	ARTICLE	IF	CITATIONS
468	Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53â€™MDM2 Interaction Useful in Targeted Cancer Therapy. <i>Topics in Current Chemistry</i> , 2017, 375, 3.	3.0	61
470	Advancement of the Emerging Field of RNA Nanotechnology. <i>ACS Nano</i> , 2017, 11, 1142-1164.	7.3	276
471	Harnessing benefit from targeting tumor associated carbohydrate antigens. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 323-331.	1.4	10
472	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 17-28.	1.6	130
473	Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma. <i>Oncogene</i> , 2017, 36, 3025-3036.	2.6	21
474	Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells. <i>Oncology Letters</i> , 2017, 14, 5563-5568.	0.8	3
475	Exploration of Zinc Oxide Nanoparticles as a Multitarget and Multifunctional Anticancer Nanomedicine. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 39971-39984.	4.0	140
476	Treatment of renal cell carcinoma: Current status and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 507-524.	157.7	583
477	IGF system targeted therapy: Therapeutic opportunities for ovarian cancer. <i>Cancer Treatment Reviews</i> , 2017, 60, 90-99.	3.4	65
478	Large Amino Acid Transporter 1 Selective Liposomes of <sc> </sc>-DOPA Functionalized Amphiphile for Combating Glioblastoma. <i>Molecular Pharmaceutics</i> , 2017, 14, 3834-3847.	2.3	53
479	Immune checkpoint inhibitors in renal cell carcinoma. <i>Clinical Science</i> , 2017, 131, 2627-2642.	1.8	62
480	Cancer Immunotherapy: Friend or Foe of Mental Health?. , 2017, , 789-823.		0
481	Hollow MnO ₂ as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. <i>Nature Communications</i> , 2017, 8, 902.	5.8	1,124
482	Increased NK cell immunity in a transgenic mouse model of NKp46 overexpression. <i>Scientific Reports</i> , 2017, 7, 13090.	1.6	15
483	Synthesis of BSAâ€™Coated BiO@Bi₂S₃ Semiconductor Heterojunction Nanoparticles and Their Applications for Radio/Photodynamic/Photothermal Synergistic Therapy of Tumor. <i>Advanced Materials</i> , 2017, 29, 1704136.	11.1	257
484	Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms. <i>Cellular Immunology</i> , 2017, 322, 1-14.	1.4	114
485	Efferocytosis of dying cells differentially modulate immunological outcomes in tumor microenvironment. <i>Immunological Reviews</i> , 2017, 280, 149-164.	2.8	65
486	Nanotechnology for Multimodal Synergistic Cancer Therapy. <i>Chemical Reviews</i> , 2017, 117, 13566-13638.	23.0	1,392

#	ARTICLE	IF	CITATIONS
487	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 527-537.	3.3	59
488	mTOR co-targeting strategies for head and neck cancer therapy. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 491-502.	2.7	46
489	A Prozone-Like Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor. <i>Pharmacology</i> , 2017, 100, 229-242.	0.9	4
490	Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. <i>Clinical Cancer Research</i> , 2017, 23, 6165-6177.	3.2	249
491	The Weak Link: Optimization of the Ligand-Nanoparticle Interface To Enhance Cancer Cell Targeting by Polymer Micelles. <i>Nano Letters</i> , 2017, 17, 5995-6005.	4.5	15
492	Second-line systemic therapy in metastatic renal-cell carcinoma: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 640-646.	0.8	14
493	A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles. <i>Pharmacological Research</i> , 2017, 126, 77-83.	3.1	16
494	Inhibiting Metastasis and Preventing Tumor Relapse by Triggering Host Immunity with Tumor-Targeted Photodynamic Therapy Using Photosensitizer-Loaded Functional Nanographenes. <i>ACS Nano</i> , 2017, 11, 10147-10158.	7.3	164
495	Immunobiology of the IL-15/IL-15R α complex as an antitumor and antiviral agent. <i>Cytokine and Growth Factor Reviews</i> , 2017, 38, 10-21.	3.2	108
496	Prophetic medicine as potential functional food elements in the intervention of cancer: A review. <i>Biomedicine and Pharmacotherapy</i> , 2017, 95, 614-648.	2.5	32
497	New treatment options for metastatic renal cell carcinoma. <i>ESMO Open</i> , 2017, 2, e000185.	2.0	60
498	Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines. <i>Cellular Immunology</i> , 2017, 319, 35-42.	1.4	27
499	The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. <i>Surgical Oncology</i> , 2017, 26, 368-376.	0.8	67
500	Thermosensitive micellar hydrogel for enhanced anticancer therapy through redox modulation mediated combinational effects. <i>RSC Advances</i> , 2017, 7, 34755-34762.	1.7	4
501	Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment. <i>Pharmacogenomics</i> , 2017, 18, 1179-1192.	0.6	4
502	Checkpoint inhibitors in the treatment of urological malignancies. <i>ESMO Open</i> , 2017, 2, e000165.	2.0	21
503	Cytotoxic T lymphocytes promote cytarabine-induced acute myeloid leukemia cell apoptosis via inhibiting Bcl-2 expression. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 1081-1085.	0.8	7
505	miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes. <i>Pharmacogenomics</i> , 2017, 18, 1671-1682.	0.6	35

#	ARTICLE	IF	CITATIONS
506	Harnessing designed nanoparticles: Current strategies and future perspectives in cancer immunotherapy. <i>Nano Today</i> , 2017, 17, 23-37.	6.2	69
507	Stability of Tumor Growth Under Immunotherapy: A Computational Study. <i>Biophysical Reviews and Letters</i> , 2017, 12, 69-85.	0.9	3
508	Immunotherapy-based combinations: current status and perspectives. <i>Current Opinion in Oncology</i> , 2017, 29, 382-394.	1.1	7
509	Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. <i>Drug Discovery Today</i> , 2017, 22, 1686-1696.	3.2	66
510	Addressing current challenges in cancer immunotherapy with mathematical and computational modelling. <i>Journal of the Royal Society Interface</i> , 2017, 14, 20170150.	1.5	71
511	Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. , 2017, 5, 4.		15
512	Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen. <i>Immunotherapy</i> , 2017, 9, 629-635.	1.0	7
513	Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations. <i>American Journal of Roentgenology</i> , 2017, 209, 567-575.	1.0	26
514	Ovarian Cancers. , 2017, , .		1
515	Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 149-159.	2.0	24
516	Photo- and thermo-responsive multicompartiment hydrogels for synergistic delivery of gemcitabine and doxorubicin. <i>Journal of Controlled Release</i> , 2017, 259, 149-159.	4.8	84
517	Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment. <i>Cancer Research</i> , 2017, 77, 520-531.	0.4	18
518	High-Intensity Focused Ultrasound“ and Radiation Therapy“Induced Immuno-Modulation: Comparison and Potential Opportunities. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 398-411.	0.7	27
519	Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2017, 9, e1421.	3.3	72
520	Preparation, Characterization and Cytotoxic Effects of Pegylated Nanoliposomal Containing Carboplatin on Ovarian Cancer Cell Lines. <i>Indian Journal of Clinical Biochemistry</i> , 2017, 32, 230-234.	0.9	29
521	Preliminary study of mechanism of action of SN38 derivatives. Physicochemical data, evidence of interaction and alkylation of DNA octamer d(GCGATCGC) ₂ . <i>Magnetic Resonance in Chemistry</i> , 2017, 55, 128-136.	1.1	8
522	Synergistic effect of programmed cell death protein-1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine. <i>Archives of Virology</i> , 2017, 162, 333-346.	0.9	12
523	Potential applications of nanoparticles in cancer immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 63-74.	1.4	35

#	ARTICLE	IF	CITATIONS
524	APOBEC3A intratumoral DNA electroporation in mice. <i>Gene Therapy</i> , 2017, 24, 74-83.	2.3	1
526	Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy. <i>BMC Cancer</i> , 2017, 17, 602.	1.1	17
527	Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1295-1306.	2.0	11
528	Genetic Polymorphisms of Insulin-Like Growth Factor 1 Are Associated with Osteosarcoma Risk and Prognosis. <i>Medical Science Monitor</i> , 2017, 23, 5892-5898.	0.5	17
529	Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2047-2063.	2.0	26
530	CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer. <i>Theranostics</i> , 2017, 7, 67-80.	4.6	31
531	Important factors for cell-membrane permeabilization by gold nanoparticles activated by nanosecond-laser irradiation. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 5659-5672.	3.3	22
532	Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites. <i>Theranostics</i> , 2017, 7, 751-763.	4.6	111
533	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2017, Volume 7, 1-11.	5.5	49
534	CpG oligodeoxynucleotides augment antitumor efficacy of folate receptor β based DNA vaccine. <i>Oncology Reports</i> , 2017, 37, 3441-3448.	1.2	6
535	Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles. <i>Frontiers in Immunology</i> , 2017, 8, 69.	2.2	32
536	Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies. <i>Frontiers in Oncology</i> , 2017, 7, 202.	1.3	107
537	Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells. <i>BioMed Research International</i> , 2017, 2017, 1-14.	0.9	21
538	Targeting the Pd-1 Pathway in Renal Cell Carcinoma: A Review. <i>Journal of Onco-Nephrology</i> , 2017, 1, 179-187.	0.3	1
539	Update on immune checkpoint inhibitors in gynecological cancers. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e20.	1.0	49
540	Cancer and Treatment Modalities. <i>Current Cancer Therapy Reviews</i> , 2017, 13, .	0.2	5
541	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 146.	6.9	77
542	The immunomodulatory activities of licorice polysaccharides (<i>Glycyrrhiza uralensis</i> Fisch.) in CT 26 tumor-bearing mice. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 536.	3.7	90

#	ARTICLE	IF	CITATIONS
543	Tipping Tumor Microenvironment against Drug Resistance. Journal of Oncology Translational Research, 2017, 01, .	0.2	2
544	The combination of checkpoint immunotherapy and targeted therapy in cancer. Annals of Translational Medicine, 2017, 5, 388-388.	0.7	54
545	Cellular immunity augmentation in mainstream oncologic therapy. Cancer Biology and Medicine, 2017, 14, 121.	1.4	8
546	Bisdemethoxycurcumin in combination with α -PD-L1 antibody boosts immune response against bladder cancer. OncoTargets and Therapy, 2017, Volume 10, 2675-2683.	1.0	54
547	Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer. OncoTargets and Therapy, 2017, Volume 10, 1101-1110.	1.0	13
548	Pediatric hepatocellular carcinoma: challenges and solutions. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 15-21.	1.8	49
549	Chemotherapy resistance mechanisms in advanced skin cancer. Oncology Reviews, 2017, 11, 326.	0.8	83
550	Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget, 2017, 8, 2874-2889.	0.8	58
551	Microenvironmental regulation of the progression of oral potentially malignant disorders towards malignancy. Oncotarget, 2017, 8, 81617-81635.	0.8	17
552	TINTIN. , 2017, , .		0
553	Established and Novel Prognostic Biomarkers in Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 548-560.	1.8	21
554	Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma. Translational Lung Cancer Research, 2017, 6, 325-334.	1.3	21
555	Cytochrome P450 1B1 promotes cancer cell survival via specificity protein 1 (Sp1)-mediated suppression of death receptor 4. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2018, 81, 278-287.	1.1	11
556	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. Current Treatment Options in Oncology, 2018, 19, 16.	1.3	5
557	Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma. Current Oncology Reports, 2018, 20, 41.	1.8	16
558	Immunostimulation and Immunosuppression: Nanotechnology on the Brink. Small Methods, 2018, 2, 1700347.	4.6	32
559	The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-l1 antibodies in tumor immunotherapy in China. Medicine (United States), 2018, 97, e0276.	0.4	5
560	Chitoooligosaccharide: An evaluation of physicochemical and biological properties with the proposition for determination of thermal degradation products. Biomedicine and Pharmacotherapy, 2018, 102, 438-451.	2.5	65

#	ARTICLE	IF	CITATIONS
561	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365.	3.1	79
562	Using immunotherapy to boost the abscopal effect. <i>Nature Reviews Cancer</i> , 2018, 18, 313-322.	12.8	844
563	Encoding materials for programming a temporal sequence of actions. <i>Journal of Materials Chemistry B</i> , 2018, 6, 1433-1448.	2.9	5
564	Targeting histone deacetylase and NF- κ B signaling as a novel therapy for Mucoepidermoid Carcinomas. <i>Scientific Reports</i> , 2018, 8, 2065.	1.6	20
565	Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability. <i>Scientific Reports</i> , 2018, 8, 2274.	1.6	38
566	Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. <i>Nature Protocols</i> , 2018, 13, 335-357.	5.5	32
567	The differences in the assessments of side effects at an oncology outpatient clinic. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 386-393.	1.0	7
568	Panitumumab-Conjugated and Platinum-Cored pH-Sensitive Apoferritin Nanocages for Colorectal Cancer-Targeted Therapy. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 6096-6106.	4.0	28
569	Blocking PD-1/PD-L1 in Genitourinary Malignancies. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 20-30.	1.0	17
570	Transferrin-Copper Nanocluster-Doxorubicin Nanoparticles as Targeted Theranostic Cancer Nanodrug. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 3282-3294.	4.0	94
571	Therapeutic Cancer Vaccines: How Much Closer Are We?. <i>BioDrugs</i> , 2018, 32, 1-7.	2.2	15
572	PD-1 Blockade in Renal Cell Carcinoma. , 2018, , 345-355.		0
573	Improving immune-vascular crosstalk for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 195-203.	10.6	340
574	Antigen-Directed Fabrication of a Multifunctional Nanovaccine with Ultrahigh Antigen Loading Efficiency for Tumor Photothermal-Immunotherapy. <i>Advanced Materials</i> , 2018, 30, 1704408.	11.1	143
575	Caspase-dependent apoptosis induced by two synthetic halogenated flavanones, 3,7-dichloroflavanone and 3,6-dichloroflavanone, on human breast and prostate cancer cells. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2018, 54, 136-146.	0.7	5
576	Epigenetic Pharmacology. , 2018, , 1551-1575.		0
577	Treatment of Metastatic Renal Cell Carcinoma: Latest Evidence and Ongoing Challenges. <i>Clinical Medicine Insights Urology</i> , 2018, 11, 117956111876575.	0.4	1
578	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 3108-3118.	3.2	200

#	ARTICLE	IF	CITATIONS
579	HDAC inhibitors as epigenetic regulators for cancer immunotherapy. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 98, 65-74.	1.2	61
580	Kinase inhibitors: the road ahead. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 353-377.	21.5	679
581	Standing in the GAP : To formulate a novel radioimmunotherapy regime to improve the long-term outcome in breast cancer. <i>Immunotherapy</i> , 2018, 10, 255-263.	1.0	2
582	Nearâ€infraredâ€Lightâ€Activatable Nanomaterialâ€Mediated Phototheranostic Nanomedicines: An Emerging Paradigm for Cancer Treatment. <i>Advanced Materials</i> , 2018, 30, e1706320.	11.1	414
583	Safety of Combined Treatment With Monoclonal Antibodies and <i>Viscum album</i> L Preparations. <i>Integrative Cancer Therapies</i> , 2018, 17, 41-51.	0.8	16
584	Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine. <i>Science and Engineering Ethics</i> , 2018, 24, 307-322.	1.7	29
585	Uncovering the role of brainâ€derived neurotrophic factor/tyrosine kinase receptor B signaling in head and neck malignancies. <i>Journal of Oral Pathology and Medicine</i> , 2018, 47, 221-227.	1.4	21
586	Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Nonâ€Small-Cell Lung Cancer: Where Do We Stand?. <i>Clinical Lung Cancer</i> , 2018, 19, 1-11.	1.1	48
587	<sc>PIKK</sc>ing a way to regulate inflammation. <i>Immunology and Cell Biology</i> , 2018, 96, 8-20.	1.0	11
588	Nanostructured chitosan composites for cancer therapy: A review. <i>International Journal of Polymeric Materials and Polymeric Biomaterials</i> , 2018, 67, 879-888.	1.8	3
589	PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene. <i>Gene</i> , 2018, 638, 20-25.	1.0	87
590	New Targets for Therapy in Lung Cancer. , 2018, , 479-489.e6.		1
591	PI3K: A Crucial Piece in the RAS Signaling Puzzle. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a031450.	2.9	38
592	Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer. <i>Oncolmmunology</i> , 2018, 7, e1376155.	2.1	34
593	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	7.7	392
594	Molecular Diagnosis and Targeting of Biliary Tract Cancer. <i>Current Human Cell Research and Applications</i> , 2018, , 111-125.	0.1	0
596	Drug development in the era of precision medicine. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 183-196.	21.5	294
597	Tetrandrine and cancer â€ An overview on the molecular approach. <i>Biomedicine and Pharmacotherapy</i> , 2018, 97, 624-632.	2.5	84

#	ARTICLE	IF	CITATIONS
598	Paclitaxel-loaded folate-coated long circulating and pH-sensitive liposomes as a potential drug delivery system: A biodistribution study. <i>Biomedicine and Pharmacotherapy</i> , 2018, 97, 489-495.	2.5	54
600	Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. <i>Current Cancer Research</i> , 2018, , 243-280.	0.2	0
601	Camptothecin prodrug nanomicelle based on a boronate ester-linked diblock copolymer as the carrier of doxorubicin with enhanced cellular uptake. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2018, 29, 160-180.	1.9	11
602	The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 381-392.	2.0	113
603	Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 393-401.	2.0	15
604	Toxicities with targeted therapies after immunotherapy in metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 600-604.	0.6	10
605	Two birds, one stone: hesperetin alleviates chemotherapy-induced diarrhea and potentiates tumor inhibition. <i>Oncotarget</i> , 2018, 9, 27958-27973.	0.8	11
606	Patterns of Response and Progression to Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 169-178.	1.8	196
607	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3126-3133.	0.8	52
608	Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 3583-3616.	1.4	118
609	Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches. , 2018, , 260-260.		0
610	Ganoderma lucidum Polysaccharides as An Anti-cancer Agent. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 667-674.	0.9	116
611	Network Pharmacology to Unveil the Biological Basis of Health-Strengthening Herbal Medicine in Cancer Treatment. <i>Cancers</i> , 2018, 10, 461.	1.7	83
612	Immune checkpoint inhibitors in cancer therapy. <i>Journal of Biomedical Research</i> , 2018, 32, 317.	0.7	101
613	Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. <i>Frontiers in Pharmacology</i> , 2018, 9, 1300.	1.6	602
614	Long-circulating and fusogenic liposomes loaded with a glucoevatromonoside derivative induce potent antitumor response. <i>Biomedicine and Pharmacotherapy</i> , 2018, 108, 1152-1161.	2.5	10
615	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. <i>Journal of Hematology and Oncology</i> , 2018, 11, 120.	6.9	333
616	The application of nanotechnology in immune checkpoint blockade for cancer treatment. <i>Journal of Controlled Release</i> , 2018, 290, 28-45.	4.8	67

#	ARTICLE	IF	CITATIONS
617	A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. <i>Cell</i> , 2018, 175, 313-326.	13.5	985
618	Mathematical Analysis of Cytokine-Induced Differentiation of Granulocyte-Monocyte Progenitor Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2048.	2.2	17
619	Mannose-Functionalized Nanoscaffolds for Targeted Delivery in Biomedical Applications. <i>Chemistry - an Asian Journal</i> , 2018, 13, 3448-3459.	1.7	43
620	Poly-Gamma-Glutamic Acid (γ -PGA)-Based Encapsulation of Adenovirus to Evade Neutralizing Antibodies. <i>Molecules</i> , 2018, 23, 2565.	1.7	31
621	Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. <i>Cytotherapy</i> , 2018, 20, 1309-1323.	0.3	16
622	Nanomedicines guided nanoimaging probes and nanotherapeutics for early detection of lung cancer and abolishing pulmonary metastasis: Critical appraisal of newer developments and challenges to clinical transition. <i>Journal of Controlled Release</i> , 2018, 292, 29-57.	4.8	41
623	An ecosystem framework for understanding and treating disease. <i>Evolution, Medicine and Public Health</i> , 2018, 2018, 270-286.	1.1	11
624	A Novel Platform for Cancer Vaccines: Antigen-Selective Delivery to Splenic Marginal Zone B Cells via Repeated Injections of PEGylated Liposomes. <i>Journal of Immunology</i> , 2018, 201, 2969-2976.	0.4	25
625	Epithelial-mesenchymal transition: Initiation by cues from chronic inflammatory tumor microenvironment and termination by anti-inflammatory compounds and specialized pro-resolving lipids. <i>Biochemical Pharmacology</i> , 2018, 158, 261-273.	2.0	26
626	STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 5948-5962.	3.2	59
627	Uncovering the underlying physical mechanism for cancer-immunity of MHC class I diversity. <i>Biochemical and Biophysical Research Communications</i> , 2018, 504, 532-537.	1.0	3
628	Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression. <i>Frontiers in Endocrinology</i> , 2018, 9, 483.	1.5	114
629	Cross-talk between lung cancer and bones results in neutrophils that promote tumor progression. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 779-790.	2.7	20
630	Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. <i>Clinical Cancer Research</i> , 2018, 24, 4110-4118.	3.2	77
631	A multifunctional DNA nano-scorpion for highly efficient targeted delivery of mRNA therapeutics. <i>Scientific Reports</i> , 2018, 8, 10196.	1.6	13
632	Growth Factor Signaling Pathways and Targeted Therapy. , 2018, , 305-322.		0
633	Detection of the Cell Cycle-Regulated Negative Feedback Phosphorylation of Mitogen-Activated Protein Kinases in Breast Carcinoma using Nanofluidic Proteomics. <i>Scientific Reports</i> , 2018, 8, 9991.	1.6	10
634	Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1843-1849.	2.8	52

#	ARTICLE	IF	CITATIONS
635	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1602.	1.8	48
636	Potentiating cancer vaccine efficacy in liver cancer. <i>Oncolimmunology</i> , 2018, 7, e1488564.	2.1	26
637	Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy. <i>Advanced Functional Materials</i> , 2018, 28, 1802540.	7.8	92
638	TGF- β 1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy. <i>Oncolimmunology</i> , 2018, 7, e1490853.	2.1	46
639	Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. <i>Cancer Treatment Reviews</i> , 2018, 69, 215-223.	3.4	19
640	Oncostatin M treatment increases the responsiveness toward cisplatin-based chemoradiotherapy in cervical cancer cells in a STAT3-dependent manner. <i>Oncology Letters</i> , 2018, 16, 3351-3358.	0.8	6
641	Reinforcing the Functionality of Mononuclear Phagocyte System to Control Tuberculosis. <i>Frontiers in Immunology</i> , 2018, 9, 193.	2.2	35
642	How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive. <i>Frontiers in Immunology</i> , 2018, 9, 262.	2.2	91
643	T-Cell-Specific Loss of the PI-3-Kinase p110 α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response. <i>Frontiers in Immunology</i> , 2018, 9, 332.	2.2	13
644	Targeting the Epidermal Growth Factor Receptor Can Counteract the Inhibition of Natural Killer Cell Function Exerted by Colorectal Tumor-Associated Fibroblasts. <i>Frontiers in Immunology</i> , 2018, 9, 1150.	2.2	24
645	Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. <i>Frontiers in Oncology</i> , 2018, 8, 202.	1.3	35
646	Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy. <i>Acta Biomaterialia</i> , 2018, 77, 228-239.	4.1	41
647	Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1340.	1.8	61
648	Antiproliferative and proapoptotic effects of DODAC/synthetic phosphoethanolamine on hepatocellular carcinoma cells. <i>BMC Pharmacology & Toxicology</i> , 2018, 19, 44.	1.0	6
649	Bioinspired Hybrid Protein Oxygen Nanocarrier Amplified Photodynamic Therapy for Eliciting Anti-tumor Immunity and Abscopal Effect. <i>ACS Nano</i> , 2018, 12, 8633-8645.	7.3	301
650	Peptide Nanophotonics: From Optical Waveguiding to Precise Medicine and Multifunctional Biochips. <i>Small</i> , 2018, 14, e1801147.	5.2	34
651	Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report. <i>BMC Cancer</i> , 2018, 18, 212.	1.1	16
652	Safety and efficacy of tamsulosin as second line treatment for patients with recurrent bladder cancer. <i>BMC Cancer</i> , 2018, 18, 194.	1.1	18

#	ARTICLE	IF	CITATIONS
653	Kinase-targeted cancer therapies: progress, challenges and future directions. <i>Molecular Cancer</i> , 2018, 17, 48.	7.9	796
654	Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. <i>Future Oncology</i> , 2018, 14, 2663-2676.	1.1	105
655	Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1440930.	2.1	30
656	Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?. <i>Current Cancer Drug Targets</i> , 2018, 18, 139-152.	0.8	7
657	Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies. <i>Current Cancer Drug Targets</i> , 2018, 18, 202-208.	0.8	9
658	Self-assembly synthesis of vaporeotide-gold hybrid nanoflower for photothermal antitumor activity. <i>Materials Science and Engineering C</i> , 2018, 93, 716-723.	3.8	15
659	Non-thermal plasma induces immunogenic cell death <i>in vivo</i> in murine CT26 colorectal tumors. <i>Oncolmmunology</i> , 2018, 7, e1484978.	2.1	111
660	Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer. <i>PLoS ONE</i> , 2018, 13, e0189582.	1.1	16
661	Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. <i>Cancer Treatment Reviews</i> , 2018, 69, 177-187.	3.4	194
662	A Review of Hydrogen Sulfide Synthesis, Metabolism, and Measurement: Is Modulation of Hydrogen Sulfide a Novel Therapeutic for Cancer?. <i>Antioxidants and Redox Signaling</i> , 2019, 31, 1-38.	2.5	293
663	Photothermal therapy enhanced the effectiveness of imiquimod against refractory cutaneous warts through boosting immune responses. <i>Journal of Biophotonics</i> , 2019, 12, e201800149.	1.1	7
664	Materials-Based Cancer Immunotherapies. , 2019, , 715-739.		2
665	Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID ^h mice. <i>Oncology Letters</i> , 2019, 18, 1539-1547.	0.8	6
666	Engineering patient-specific cancer immunotherapies. <i>Nature Biomedical Engineering</i> , 2019, 3, 768-782.	11.6	123
667	Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1331-1340.	2.0	3
668	Clinical Scenarios Emerging from Combined Immunophenotypic, Molecular and Morphologic Analysis of Pancreatic Cancer: the Good, the Bad and the Ugly Scenario. <i>Cancers</i> , 2019, 11, 968.	1.7	3
669	A cell-engineered system to assess tumor cell sensitivity to CD8 ⁺ T cell-mediated cytotoxicity. <i>Oncolmmunology</i> , 2019, 8, 1-10.	2.1	51
670	PEG-Derivatized Dual-Functional Nanomicelles for Improved Cancer Therapy. <i>Frontiers in Pharmacology</i> , 2019, 10, 808.	1.6	33

#	ARTICLE	IF	CITATIONS
671	miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 900.	1.7	23
672	HDAC2-dependent miRNA signature in acute myeloid leukemia. <i>FEBS Letters</i> , 2019, 593, 2574-2584.	1.3	15
673	Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 405-414.	1.1	5
674	Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 21, 102034.	1.7	50
675	Molecular pathogenesis of gallbladder cancer: An update. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2019, 816-818, 111674.	0.4	39
676	Activation of BDNF/TrkB/Akt pathway is associated with aggressiveness and unfavorable survival in oral squamous cell carcinoma. <i>Oral Diseases</i> , 2019, 25, 1925-1936.	1.5	23
677	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3021-3036.	1.2	20
678	Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses. <i>Chemical Society Reviews</i> , 2019, 48, 5506-5526.	18.7	209
679	Factors influencing the outcome of stereotactic radiosurgery in patients with five or more brain metastases. <i>Current Oncology</i> , 2019, 26, .	0.9	5
680	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102812.	2.0	7
681	Dihydrochalcone Derivative Induces Breast Cancer Cell Apoptosis via Intrinsic, Extrinsic, and ER Stress Pathways but Abolishes EGFR/MAPK Pathway. <i>BioMed Research International</i> , 2019, 2019, 1-18.	0.9	12
682	A small cytotoxic peptide from frog elicits potent antitumor immunity to prevent local tumor growth and metastases. <i>Future Medicinal Chemistry</i> , 2019, 11, 2505-2525.	1.1	4
683	Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 1004.	1.3	23
684	Phagocytosis checkpoints as new targets for cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 568-586.	12.8	557
685	Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 857.	1.3	12
686	Enzyme-Driven Membrane-Targeted Chimeric Peptide for Enhanced Tumor Photodynamic Immunotherapy. <i>ACS Nano</i> , 2019, 13, 11249-11262.	7.3	112
687	Efficient ovalbumin delivery using a novel multifunctional micellar platform for targeted melanoma immunotherapy. <i>International Journal of Pharmaceutics</i> , 2019, 560, 1-10.	2.6	21
688	Chitosan oligosaccharide (COS): An overview. <i>International Journal of Biological Macromolecules</i> , 2019, 129, 827-843.	3.6	313

#	ARTICLE	IF	CITATIONS
689	Supramolecular Tripeptide Hydrogel Assembly with 5-Fluorouracil. <i>Gels</i> , 2019, 5, 5.	2.1	30
690	Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor. <i>Cellular and Molecular Bioengineering</i> , 2019, 12, 357-373.	1.0	12
691	Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis. <i>Advanced Science</i> , 2019, 6, 1802281.	5.6	50
692	Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2970.	1.8	53
693	Sequential Protein-Responsive Nanophotosensitizer Complex for Enhancing Tumor-Specific Therapy. <i>ACS Nano</i> , 2019, 13, 6702-6710.	7.3	52
694	The 100 top-cited studies in cancer immunotherapy. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 2282-2292.	1.9	26
695	Enrichment of novel quinazoline derivatives with high antitumor activity in mitochondria tracked by its self-fluorescence. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 417-432.	2.6	16
696	Solid Tumors Challenges and New Insights of CAR T Cell Engineering. <i>Stem Cell Reviews and Reports</i> , 2019, 15, 619-636.	1.7	71
697	The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1419-1428.	1.0	15
698	<p>Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4619-4630.	0.9	5
699	Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. <i>Cancer Letters</i> , 2019, 458, 123-135.	3.2	40
700	A Unique Family of Neuronal Signaling Proteins Implicated in Oncogenesis and Tumor Suppression. <i>Frontiers in Oncology</i> , 2019, 9, 289.	1.3	32
701	Immunomodulation and Immunotherapy for Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 189-212.	0.0	1
702	Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. <i>Oncolimmunology</i> , 2019, 8, e1581556.	2.1	68
703	How many samples are needed to infer truly clonal mutations from heterogenous tumours?. <i>BMC Cancer</i> , 2019, 19, 403.	1.1	21
704	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. <i>Cancer Treatment Reviews</i> , 2019, 76, 22-32.	3.4	224
705	Gastric Cancer In The Precision Medicine Era. <i>Current Clinical Pathology</i> , 2019, , .	0.0	2
706	Cancer drug resistance: A fleet to conquer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 14213-14225.	1.2	46

#	ARTICLE	IF	CITATIONS
707	Beyond the tumour microenvironment. <i>International Journal of Cancer</i> , 2019, 145, 2611-2618.	2.3	71
708	A ∞ -Dual-Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2465-2475.	1.6	16
709	Factors Influencing the Outcome of Stereotactic Radiosurgery in Patients With Five or More Brain Metastases. <i>Current Oncology</i> , 2019, 26, 64-69.	0.9	9
710	Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages. <i>Advanced Materials</i> , 2019, 31, e1808303.	11.1	223
711	NIR-Triggered Phototherapy and Immunotherapy via an Antigen-Capturing Nanoplatfrom for Metastatic Cancer Treatment. <i>Advanced Science</i> , 2019, 6, 1802157.	5.6	221
712	Reactive Oxygen Species (ROS)-Based Nanomedicine. <i>Chemical Reviews</i> , 2019, 119, 4881-4985.	23.0	1,519
713	Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. <i>Gastroenterology</i> , 2019, 156, 2056-2072.	0.6	300
714	Enhanced Antitumor Immune Response in 2^{-5} Oligoadenylate Synthetase-Like 1- (OASL1-) Deficient Mice upon Cisplatin Chemotherapy and Radiotherapy. <i>Journal of Immunology Research</i> , 2019, 2019, 1-14.	0.9	3
715	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019, 39, 503-519.	1.1	26
716	<i>LINC00261</i> Is an Epigenetically Regulated Tumor Suppressor Essential for Activation of the DNA Damage Response. <i>Cancer Research</i> , 2019, 79, 3050-3062.	0.4	75
717	Self-antigen MASH2 combined with the AS15 immunostimulant induces tumor protection in colorectal cancer mouse models. <i>PLoS ONE</i> , 2019, 14, e0210261.	1.1	8
718	Mesoporous silica/organosilica nanoparticles: Synthesis, biological effect and biomedical application. <i>Materials Science and Engineering Reports</i> , 2019, 137, 66-105.	14.8	119
719	ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2019, 25, 3392-3403.	3.2	144
720	Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. <i>Current Oncology Reports</i> , 2019, 21, 24.	1.8	16
721	Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics. <i>Clinical Cancer Research</i> , 2019, 25, 4211-4223.	3.2	85
722	Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 18.	6.9	79
723	Advances in immunotherapy delivery from implantable and injectable biomaterials. <i>Acta Biomaterialia</i> , 2019, 88, 15-31.	4.1	127
724	Phase III trials in ovarian cancer: The evolving landscape of front line therapy. <i>Gynecologic Oncology</i> , 2019, 153, 436-444.	0.6	17

#	ARTICLE	IF	CITATIONS
725	Introductory Chapter: Are We There Yet? The Long and Winding Road to Cancer Immunotherapy. , 2019, , .		0
726	Immunotherapy for Treatment of Cancer. , 2019, , .		4
727	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. Oncologist, 2019, 24, 338-348.	1.9	34
728	Inhibition of STAT3 signaling induces apoptosis and suppresses growth of lung cancer: good and bad. Laboratory Animal Research, 2019, 35, 30.	1.1	21
729	Triazol: a privileged scaffold for proteolysis targeting chimeras. Future Medicinal Chemistry, 2019, 11, 2919-2973.	1.1	32
730	Multi Gene Genetic Program Modelling on L-Asparaginase Activity of Bacillus Stratosphericus. Chemical Product and Process Modeling, 2019, .	0.5	0
731	PEGylated reduced-graphene oxide hybridized with Fe ₃ O ₄ nanoparticles for cancer photothermal-immunotherapy. Journal of Materials Chemistry B, 2019, 7, 7406-7414.	2.9	68
732	Reversal of Epithelialâ€“Mesenchymal Transition by Natural Anti-Inflammatory and Pro-Resolving Lipids. Cancers, 2019, 11, 1841.	1.7	15
733	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers, 2019, 11, 1926.	1.7	27
734	Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets. Cancers, 2019, 11, 1972.	1.7	8
735	Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity. Journal of the National Cancer Institute, 2019, 111, 399-408.	3.0	58
736	Regioselective alkylation reaction of the 2â€²-deoxyctidine with 9-aminomethyl derivatives of SN38. Journal of Molecular Structure, 2019, 1176, 298-302.	1.8	5
737	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 199-224.	3.3	53
738	Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation. Molecular Pharmaceutics, 2019, 16, 561-572.	2.3	19
739	Bifunctional Fusion Proteins Derived from Tumstatin and 4-1BBL for Targeted Cancer Therapy. Molecular Pharmaceutics, 2019, 16, 867-876.	2.3	7
740	Progress in Tumorâ€“Associated Macrophages: From Bench to Bedside. Advanced Biology, 2019, 3, e1800232.	3.0	12
741	Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature. Molecular Pharmaceutics, 2019, 16, 339-348.	2.3	66
742	Introduction of Z-GP scaffold into procarbazine reduces spermatotoxicity and myelosuppression. Bioorganic Chemistry, 2019, 83, 461-467.	2.0	1

#	ARTICLE	IF	CITATIONS
743	Selecting chemotherapy for pancreatic cancer: Far away or so close?. <i>Seminars in Oncology</i> , 2019, 46, 39-47.	0.8	12
744	Low Molecular Weight Heparin-Coated and Dendrimer-Based Core-Shell Nanoplatform with Enhanced Immune Activation and Multiple Anti-Metastatic Effects for Melanoma Treatment. <i>Theranostics</i> , 2019, 9, 337-354.	4.6	46
745	ACC1 determines memory potential of individual CD4+ T cells by regulating de novo fatty acid biosynthesis. <i>Nature Metabolism</i> , 2019, 1, 261-275.	5.1	48
746	Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. <i>Clinical Cancer Research</i> , 2019, 25, 515-523.	3.2	354
747	New developments in investigational HDAC inhibitors for the potential multimodal treatment of cachexia. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 179-189.	1.9	9
748	Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms. <i>International Immunopharmacology</i> , 2019, 67, 160-175.	1.7	33
749	Collagen Hydrogel Functionalized with Collagen-Targeting IFN α 2b Shows Apoptotic Activity in Nude Mice with Xenografted Tumors. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 272-282.	2.6	5
750	Analysis of a stochastic tumor-immune model with regime switching and impulsive perturbations. <i>Applied Mathematical Modelling</i> , 2020, 78, 482-504.	2.2	40
751	Bicistronic transfer of CDKN2A and p53 culminates in collaborative killing of human lung cancer cells in vitro and in vivo. <i>Gene Therapy</i> , 2020, 27, 51-61.	2.3	6
752	Strategies for Targeting Cancer Immunotherapy Through Modulation of the Tumor Microenvironment. <i>Regenerative Engineering and Translational Medicine</i> , 2020, 6, 29-49.	1.6	16
753	Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues. <i>Methods in Enzymology</i> , 2020, 635, 149-166.	0.4	4
754	Intra-bone donor lymphocyte infusion at relapse: clinical outcome is associated with presence of CD8+ cells in the marrow. <i>Bone Marrow Transplantation</i> , 2020, 55, 974-978.	1.3	0
755	Colorectal cancer in Saudi Arabia as the proof-of-principle model for implementing strategies of predictive, preventive, and personalized medicine in healthcare. <i>EPMA Journal</i> , 2020, 11, 119-131.	3.3	34
756	A Nanoscale Metal-Organic Framework to Mediate Photodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Enhance Antigen Presentation and Cancer Immunotherapy. <i>Angewandte Chemie</i> , 2020, 132, 1124-1128.	1.6	34
757	A Nanoscale Metal-Organic Framework to Mediate Photodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Enhance Antigen Presentation and Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 1108-1112.	7.2	144
758	Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. <i>Nanoscale</i> , 2020, 12, 413-436.	2.8	49
760	Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase. <i>European Journal of Medicinal Chemistry</i> , 2020, 189, 112041.	2.6	11
762	Polarization of tumor-associated macrophage phenotype <i>via</i> porous hollow iron nanoparticles for tumor immunotherapy <i>in vivo</i> . <i>Nanoscale</i> , 2020, 12, 130-144.	2.8	83

#	ARTICLE	IF	CITATIONS
763	Cord blood stem cell derived CD16+ NK cells eradicated acute lymphoblastic leukemia cells using with anti-CD47 antibody. <i>Life Sciences</i> , 2020, 242, 117223.	2.0	20
764	Diselenide-Pemetrexed Assemblies for Combined Cancer Immuno-, Radio-, and Chemotherapies. <i>Angewandte Chemie</i> , 2020, 132, 2722-2726.	1.6	11
765	Methods and resources to access mutation-dependent effects on cancer drug treatment. <i>Briefings in Bioinformatics</i> , 2020, 21, 1886-1903.	3.2	5
766	Amplification of tumor antigen presentation by NLGplatin to improve chemoimmunotherapy. <i>International Journal of Pharmaceutics</i> , 2020, 573, 118736.	2.6	9
767	Dual fluorescence imaging-guided programmed delivery of doxorubicin and CpG nanoparticles to modulate tumor microenvironment for effective chemo-immunotherapy. <i>Biomaterials</i> , 2020, 230, 119659.	5.7	74
768	Diselenide-Pemetrexed Assemblies for Combined Cancer Immuno-, Radio-, and Chemotherapies. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 2700-2704.	7.2	100
769	Microtubule inhibitors containing immunostimulatory agents promote cancer immunotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase. <i>European Journal of Medicinal Chemistry</i> , 2020, 187, 111949.	2.6	10
770	Design, synthesis and anticancer evaluation of 2-Amino pyrimidine linked 7-Azaindazole derivatives. <i>Chemical Data Collections</i> , 2020, 29, 100513.	1.1	4
771	Immunotherapy for Renal Cell Carcinoma. , 0, , .		0
772	Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype. <i>Theranostics</i> , 2020, 10, 11264-11277.	4.6	20
773	Cyclohepta[<i>b</i>]thiophenes as Potential Antiproliferative Agents: Design, Synthesis, <i>In Vitro</i> , and <i>In Vivo</i> Anticancer Evaluation. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 965-977.	2.5	8
774	Recent advances in targeted nanomedicine as promising antitumor therapeutics. <i>Drug Discovery Today</i> , 2020, 25, 2227-2244.	3.2	71
775	Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?. <i>Frontiers in Oncology</i> , 2020, 10, 912.	1.3	6
776	Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1544-1563.	2.9	29
777	Carrier-free nanoassembly of doxorubicin prodrug and siRNA for combinationally inducing immunogenic cell death and reversing immunosuppression. <i>Nano Today</i> , 2020, 35, 100924.	6.2	68
778	Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 568279.	1.3	11
779	Cancer cell-targeted nanoprobe for multilayer imaging of diverse biomarkers and precise photodynamic therapy. <i>Chemical Communications</i> , 2020, 56, 15208-15211.	2.2	7
780	Phytoestrogens for Cancer Prevention and Treatment. <i>Biology</i> , 2020, 9, 427.	1.3	41

#	ARTICLE	IF	CITATIONS
781	Immunoadjuvants for cancer immunotherapy: A review of recent developments. <i>Acta Biomaterialia</i> , 2020, 114, 16-30.	4.1	78
782	Recent Progress on Activatable Nanomedicines for Immunometabolic Combinational Cancer Therapy. <i>Small Structures</i> , 2020, 1, 2000026.	6.9	54
783	Comparative Study of Cancer Treatment Potential Effects of Tumor-Treating Fields and Cold Atmospheric Plasma. <i>Plasma Medicine</i> , 2020, 10, 45-59.	0.2	4
784	Intestinal microbiota regulates anti-tumor effect of disulfiram combined with Cu ²⁺ in a mice model. <i>Cancer Medicine</i> , 2020, 9, 6791-6801.	1.3	13
785	<p>Research Progress and Existing Problems for Abscopal Effect</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6695-6706.	0.9	8
786	Treating Immunologically Cold Tumors by Precise Cancer Photoimmunotherapy with an Extendable Nanoplatfom. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 40002-40012.	4.0	18
787	Covalent Organic Framework-Based Nanocomposite for Synergetic Photo-, Chemodynamic-, and Immunotherapies. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 43456-43465.	4.0	49
788	Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy. <i>Cancers</i> , 2020, 12, 2637.	1.7	40
789	2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAFV600E/C-RAF kinase inhibitory effects: Design, synthesis, in vitro cell-based and oncogenic kinase assessments. <i>European Journal of Medicinal Chemistry</i> , 2020, 208, 112756.	2.6	10
790	Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094427.	0.8	4
791	Inhibitory Monoclonal Antibodies and Their Recombinant Derivatives Targeting Surface-Exposed Carbonic Anhydrase XII on Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9411.	1.8	7
792	Opportunities for Conventional and In Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. <i>Cancers</i> , 2020, 12, 1121.	1.7	31
793	Prognostic effects of histology-based tumour microenvironment scores in resected distal bile duct cancer. <i>Histopathology</i> , 2020, 77, 402-412.	1.6	2
794	Current Advances in Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	4
795	Guillain-Barré Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming. <i>Journal of Neuroimmunology</i> , 2020, 346, 577267.	1.1	1
796	Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. <i>Genome Medicine</i> , 2020, 12, 47.	3.6	107
797	Molecular engineering of anti-PD-L1 peptide and photosensitizer for immune checkpoint blockade photodynamic-immunotherapy. <i>Chemical Engineering Journal</i> , 2020, 400, 125995.	6.6	36
798	Intensive therapy with gastropodan hemocyanins increases their antitumor properties in murine model of colon carcinoma. <i>International Immunopharmacology</i> , 2020, 84, 106566.	1.7	5

#	ARTICLE	IF	CITATIONS
799	The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target. <i>Journal of Oncology</i> , 2020, 2020, 1-15.	0.6	33
800	Selective imaging of solid tumours via the calcium-dependent high-affinity binding of a cyclic octapeptide to phosphorylated Annexin A2. <i>Nature Biomedical Engineering</i> , 2020, 4, 298-313.	11.6	31
801	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57
802	Methionine Restriction and Cancer Biology. <i>Nutrients</i> , 2020, 12, 684.	1.7	97
803	Tumor Microenvironment. <i>Cancer Treatment and Research</i> , 2020, , .	0.2	12
804	Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications. <i>Cells</i> , 2020, 9, 563.	1.8	116
805	Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy. <i>Cancers</i> , 2020, 12, 1664.	1.7	74
806	Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer. <i>Cancers</i> , 2020, 12, 1755.	1.7	37
807	B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. <i>Future Oncology</i> , 2020, 16, 1767-1791.	1.1	16
808	Deep Fluorescence Imaging by Laser-Scanning Excitation and Artificial Neural Network Processing. <i>Advanced Optical Materials</i> , 2020, 8, 2000390.	3.6	2
809	PARP inhibitors: a tsunami of indications in different malignancies. <i>Pharmacogenomics</i> , 2020, 21, 221-230.	0.6	16
810	Evaluation of the tumor-targeting efficiency and intratumor heterogeneity of anticancer drugs using quantitative mass spectrometry imaging. <i>Theranostics</i> , 2020, 10, 2621-2630.	4.6	37
811	“All-in-One” Silver Nanoprism Platform for Targeted Tumor Theranostics. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 11329-11340.	4.0	23
812	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. <i>Gastroenterology Report</i> , 2020, 8, 11-24.	0.6	68
813	FOXD3 Regulates VISTA Expression in Melanoma. <i>Cell Reports</i> , 2020, 30, 510-524.e6.	2.9	42
814	Pembrolizumab for the treatment of colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 219-226.	1.4	21
815	Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review. <i>Cancers</i> , 2020, 12, 192.	1.7	30
816	Biocompatible Chemotherapy for Leukemia by Acid-Cleavable, PEGylated FTY720. <i>Bioconjugate Chemistry</i> , 2020, 31, 673-684.	1.8	5

#	ARTICLE	IF	CITATIONS
817	BiO ₂ Nanosheets as Radiosensitizers with Catalase-Like Activity for Hypoxia Alleviation and Enhancement of the Radiotherapy of Tumors. <i>Inorganic Chemistry</i> , 2020, 59, 3482-3493.	1.9	64
819	Astaxanthin Treatment Induces Maturation and Functional Change of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice. <i>Antioxidants</i> , 2020, 9, 350.	2.2	7
820	Breast cancer: Biology, biomarkers, and treatments. <i>International Immunopharmacology</i> , 2020, 84, 106535.	1.7	307
821	Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance?. <i>Cancers</i> , 2020, 12, 774.	1.7	10
822	Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. <i>British Journal of Pharmacology</i> , 2020, 177, 2889-2903.	2.7	10
823	Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. <i>Blood</i> , 2020, 135, 597-609.	0.6	134
824	Current updates and future perspectives on the management of renal cell carcinoma. <i>Life Sciences</i> , 2021, 264, 118632.	2.0	48
825	Recent advances in nanoscale materials for antibody-based cancer theranostics. <i>Biosensors and Bioelectronics</i> , 2021, 173, 112787.	5.3	12
826	Naringin Combined with NF- κ B Inhibition and Endoplasmic Reticulum Stress Induces Apoptotic Cell Death via Oxidative Stress and the PERK/eIF2 β /ATF4/CHOP Axis in HT29 Colon Cancer Cells. <i>Biochemical Genetics</i> , 2021, 59, 159-184.	0.8	20
827	Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors. <i>Trends in Molecular Medicine</i> , 2021, 27, 75-90.	3.5	5
828	Bioengineering of nano metal-organic frameworks for cancer immunotherapy. <i>Nano Research</i> , 2021, 14, 1244-1259.	5.8	37
829	Bioengineered tissue models for the development of dynamic immuno-associated tumor models and high-throughput immunotherapy cytotoxicity assays. <i>Drug Discovery Today</i> , 2021, 26, 455-473.	3.2	2
830	Systemic dendrimer delivery of triptolide to tumor-associated macrophages improves anti-tumor efficacy and reduces systemic toxicity in glioblastoma. <i>Journal of Controlled Release</i> , 2021, 329, 434-444.	4.8	22
831	DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy. <i>Cancer Genetics</i> , 2021, 252-253, 6-24.	0.2	28
832	Fertility preservation for prepubertal boys: lessons learned from the past and update on remaining challenges towards clinical translation. <i>Human Reproduction Update</i> , 2021, 27, 433-459.	5.2	39
833	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 9-23.	1.3	5
834	Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 34-45.	0.3	1
835	AIM in Oncology., 2021, , 1-11.		0

#	ARTICLE	IF	CITATIONS
836	Current Trends in Cancer Immunotherapy. IFMBE Proceedings, 2021, , 456-461.	0.2	1
837	Cancer photo-immunotherapy: from bench to bedside. Theranostics, 2021, 11, 2218-2231.	4.6	50
838	Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo-immunotherapy. Nanoscale, 2021, 13, 17218-17235.	2.8	63
839	Mixture Cure Models in Oncology: A Tutorial and Practical Guidance. PharmacoEconomics - Open, 2021, 5, 143-155.	0.9	17
840	Immune Stimulating Antibody-Photosensitizer Conjugates via Fc-Mediated Dendritic Cell Phagocytosis and Phototriggered Immunogenic Cell Death for KRAS-Mutated Pancreatic Cancer Treatment. Small, 2021, 17, e2006650.	5.2	18
841	Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy. Future Oncology, 2021, 17, 711-722.	1.1	10
842	Investigation of singlet oxygen production property of peripherally tetra-substituted In(III)Cl phthalocyanine for photodynamic therapy. Journal of the Turkish Chemical Society, Section A: Chemistry, 2021, 8, 279-288.	0.4	2
843	Inorganic Nanoparticles Applied for Active Targeted Photodynamic Therapy of Breast Cancer. Pharmaceutics, 2021, 13, 296.	2.0	62
844	Investigating T Cell Immunity in Cancer: Achievements and Prospects. International Journal of Molecular Sciences, 2021, 22, 2907.	1.8	12
845	Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy. International Journal of Nanomedicine, 2021, Volume 16, 1631-1661.	3.3	19
846	Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. , 2021, 9, e002191.		38
847	Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy. Advanced Healthcare Materials, 2021, 10, e2002104.	3.9	47
848	Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting. Inflammopharmacology, 2021, 29, 343-366.	1.9	9
849	Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 2608.	1.8	13
850	Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Frontiers in Molecular Biosciences, 2021, 8, 635243.	1.6	22
851	Anti-angiogenic agents overcome tumour endothelial cell energy and improve immunotherapy outcomes. Nature Reviews Clinical Oncology, 2021, 18, 527-540.	12.5	162
852	Saccorhiza polyschides used to synthesize gold and silver nanoparticles with enhanced antiproliferative and immunostimulant activity. Materials Science and Engineering C, 2021, 123, 111960.	3.8	20
853	Bimodal regulation of the PRC2 complex by USP7 underlies tumorigenesis. Nucleic Acids Research, 2021, 49, 4421-4440.	6.5	14

#	ARTICLE	IF	CITATIONS
854	Cancer neoantigens as potential targets for immunotherapy. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 51-60.	1.7	24
855	Flavonoids as an effective sensitizer for anti-cancer therapy: insights into multi-faceted mechanisms and applicability towards individualized patient profiles. <i>EPMA Journal</i> , 2021, 12, 155-176.	3.3	71
856	The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	15
857	Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research. <i>Frontiers in Oncology</i> , 2021, 11, 559161.	1.3	34
858	Recent Advances in Engineered Materials for Immunotherapyâ€”Involved Combination Cancer Therapy. <i>Advanced Materials</i> , 2021, 33, e2007630.	11.1	112
859	Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients With Chronic Myelogenous Leukemia. <i>JCO Oncology Practice</i> , 2021, 17, e1811-e1820.	1.4	8
860	Thiophene Derivativeâ€”Loaded Nanoparticles Mediate Anticancer Activity Through the Inhibition of Kinases and Microtubule Assembly. <i>Advanced Therapeutics</i> , 2021, 4, 2100058.	1.6	7
861	Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma. <i>Frontiers in Oncology</i> , 2021, 11, 664853.	1.3	44
862	Fabrication of cisplatin-loaded polydopamine nanoparticles via supramolecular self-assembly for photoacoustic imaging guided chemo-photothermal cancer therapy. <i>Applied Materials Today</i> , 2021, 23, 101019.	2.3	22
863	In Situ Delivery and Production System (iDPS) of Anti-Cancer Molecules with Gene-Engineered Bifidobacterium. <i>Journal of Personalized Medicine</i> , 2021, 11, 566.	1.1	8
864	Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7926-7962.	2.9	35
865	Anti-carcinogenic Effect of Cathepsin K Inhibitor, Odanacatib with a Low Dose of Cisplatin Against Human Breast Carcinoma MCF-7 and MDA-MB231 Cells. <i>Current Cancer Therapy Reviews</i> , 2021, 17, 159-169.	0.2	0
866	Traceable metallic antigen release for enhanced cancer immunotherapy. <i>Journal of Nanoparticle Research</i> , 2021, 23, 130.	0.8	2
867	Micelles in Cancer Therapy: An Update on Preclinical and Clinical Status. <i>Recent Patents on Nanotechnology</i> , 2022, 16, 283-294.	0.7	7
868	Colloidal Assemblies Composed of Polymeric Micellar/Emulsified Systems Integrate Cancer Therapy Combining a Tumor-Associated Antigen Vaccine and Chemotherapeutic Regimens. <i>Nanomaterials</i> , 2021, 11, 1844.	1.9	2
869	Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities. <i>Cancers</i> , 2021, 13, 3652.	1.7	13
871	Tumor microenvironment/NIR-responsive carbon monoxide delivery with hollow mesoporous CuS nanoparticles for MR imaging guided synergistic therapy. <i>Materials and Design</i> , 2021, 205, 109731.	3.3	15
872	Sonodynamic Treatment Induces Selective Killing of Cancer Cells in an In Vitro Co-Culture Model. <i>Cancers</i> , 2021, 13, 3852.	1.7	11

#	ARTICLE	IF	CITATIONS
873	Plasmonâ€Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway. <i>Advanced Materials</i> , 2021, 33, e2102188.	11.1	59
874	Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. <i>Pharmacogenomics</i> , 2021, 22, 703-726.	0.6	3
875	Multiple strategies with the synergistic approach for addressing colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111704.	2.5	25
876	Iron Oxide Nanoparticles Synthesized Via Green Tea Extract for Doxorubicin Delivery. <i>Current Nanoscience</i> , 2021, 17, 646-657.	0.7	5
877	The Potential Applications of Stem Cells for Cancer Treatment. <i>Current Stem Cell Research and Therapy</i> , 2022, 17, 26-42.	0.6	2
878	Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy. <i>Nano Today</i> , 2021, 39, 101163.	6.2	18
879	Responsive Dual-Targeting Exosome as a Drug Carrier for Combination Cancer Immunotherapy. <i>Research</i> , 2021, 2021, 9862876.	2.8	17
880	Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy. <i>Applied Materials Today</i> , 2021, 24, 101149.	2.3	7
881	A multiple environment-sensitive prodrug nanomicelle strategy based on chitosan graftomer for enhanced tumor therapy of gambogic acid. <i>Carbohydrate Polymers</i> , 2021, 267, 118229.	5.1	15
882	Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy. <i>Coordination Chemistry Reviews</i> , 2021, 442, 214009.	9.5	29
883	Anticancer Activity of Some Ruthenium(III) Complexes with Quinolone Antibiotics: In Vitro Cytotoxicity, Cell Cycle Modulation, and Apoptosis-Inducing Properties in LoVo Colon Cancer Cell Line. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 8594.	1.3	7
884	Dietary suppression of MHC class II expression in intestinal epithelial cells enhances intestinal tumorigenesis. <i>Cell Stem Cell</i> , 2021, 28, 1922-1935.e5.	5.2	67
885	Antimicrobial Peptides and Their Applications in Biomedical Sector. <i>Antibiotics</i> , 2021, 10, 1094.	1.5	17
886	Anticancer Effects and Mechanisms of OSW-1 Isolated From <i>Ornithogalum saundersiae</i> : A Review. <i>Frontiers in Oncology</i> , 2021, 11, 747718.	1.3	6
887	Dual ATP/reduction-responsive polyplex to achieve the co-delivery of doxorubicin and miR-23b for the cancer treatment. <i>Colloids and Surfaces B: Biointerfaces</i> , 2021, 206, 111955.	2.5	4
888	Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study. <i>Lung Cancer</i> , 2021, 160, 111-117.	0.9	25
889	Design, synthesis, and molecular docking study of some 2-((7-chloroquinolin-4-yl) amino) benzohydrazide Schiff bases as potential Eg5 inhibitory agents. <i>Bioorganic Chemistry</i> , 2021, 116, 105381.	2.0	2
890	Design, synthesis and antitumor activity evaluation of trifluoromethyl-substituted pyrimidine derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 51, 128268.	1.0	8

#	ARTICLE	IF	CITATIONS
891	Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188598.	3.3	8
892	Tumor-targeted Gd-doped mesoporous Fe ₃ O ₄ nanoparticles for T ₁ /T ₂ MR imaging guided synergistic cancer therapy. <i>Drug Delivery</i> , 2021, 28, 787-799.	2.5	9
893	Oxide-based composites: applications in thermo-photocatalysis. <i>Catalysis Science and Technology</i> , 2021, 11, 6904-6930.	2.1	13
894	Nanocarriers for the Diagnosis and Treatment of Cancer. <i>Nanomedicine and Nanotoxicology</i> , 2021, , 223-252.	0.1	0
895	Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis. <i>Current Cancer Drug Targets</i> , 2021, 21, 55-69.	0.8	8
896	Green and efficient synthesis of thioureas, ureas, primary <i>O</i> -thiocarbamates, and carbamates in deep eutectic solvent/catalyst systems using thiourea and urea. <i>New Journal of Chemistry</i> , 0, , .	1.4	13
897	Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100442.	0.7	14
898	Immunotherapy in Colorectal Cancer: Current and Future Strategies. <i>Journal of the Anus, Rectum and Colon</i> , 2021, 5, 11-24.	0.4	59
899	Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages. <i>Nanoscale</i> , 2021, 13, 4705-4727.	2.8	33
900	Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies. <i>Clinical and Translational Medicine</i> , 2020, 10, e254.	1.7	23
901	Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors. <i>Cancer Treatment and Research</i> , 2020, 180, 251-279.	0.2	15
902	Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1257, 109-131.	0.8	7
903	Genetically Modified T-Cell Therapy for Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2014, 804, 323-340.	0.8	16
904	Vascular Endothelial Growth Factor (VEGF). , 2016, , 363-374.		6
905	Vaccine Approaches in Hepatocellular Carcinoma. , 2017, , 1-17.		1
906	The Role of Innate Immune Signaling in Regulation of Tumor-Associated Myeloid Cells. , 2015, , 25-47.		2
907	Role of the Immunological Environment in Cancer Initiation, Development and Progression. , 2013, , 1-12.		1
908	Gd-metallofullerenol drug delivery system mediated macrophage polarization enhances the efficiency of chemotherapy. <i>Journal of Controlled Release</i> , 2020, 320, 293-303.	4.8	18

#	ARTICLE	IF	CITATIONS
909	Gas plasma irradiation of breast cancers promotes immunogenicity, tumor reduction, and an abscopal effect in vivo. <i>Oncolmmunology</i> , 2021, 10, 1859731.	2.1	34
911	Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment. <i>Journal of Clinical Investigation</i> , 2016, 126, 4417-4429.	3.9	67
912	Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. <i>Journal of Clinical Investigation</i> , 2018, 128, 3425-3438.	3.9	111
913	Ligand Based Virtual Screening to Identify Potential Anti Cancer Ligands Similar to Withaferin A Targeting Indoleamine 2,3-Dioxygenase. <i>Biosciences, Biotechnology Research Asia</i> , 2014, 11, 887-893.	0.2	1
914	Myelopoietic Efficacy of Orlistat in Murine Hosts Bearing T Cell Lymphoma: Implication in Macrophage Differentiation and Activation. <i>PLoS ONE</i> , 2013, 8, e82396.	1.1	10
915	Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment. <i>PLoS ONE</i> , 2014, 9, e109992.	1.1	33
916	The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0164514.	1.1	136
917	Artesunate and chloroquine induce cytotoxic activity on cholangiocarcinoma cells via different cell death mechanisms. <i>Cellular and Molecular Biology</i> , 2018, 64, 113-118.	0.3	5
918	A Systematic Overview of Cancer Immunotherapy: An Emerging Therapy. <i>Pharmacy & Pharmacology International Journal</i> , 2017, 5, .	0.1	8
919	Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 46301-46314.	0.8	28
920	Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 55690-55703.	0.8	14
921	Inhibition of never in mitosis A (NIMA)-related kinase-4 reduces survivin expression and sensitizes cancer cells to TRAIL-induced cell death. <i>Oncotarget</i> , 2016, 7, 65957-65967.	0.8	14
922	Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma. <i>Oncotarget</i> , 2013, 4, 2237-2248.	0.8	20
923	Increased cFLIP expression in thymic epithelial tumors blocks autophagy via NF- κ B signalling. <i>Oncotarget</i> , 2017, 8, 89580-89594.	0.8	12
924	Arginine deiminase expressed <i>in vivo</i> , driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency. <i>Oncotarget</i> , 2017, 8, 37694-37704.	0.8	14
925	Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2018, 9, 11846-11857.	0.8	2
926	Constitutive activation of EGFR is associated with tumor progression and plays a prominent role in malignant phenotype of chondrosarcoma. <i>Oncotarget</i> , 2019, 10, 3166-3182.	0.8	3
927	Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies. <i>Oncotarget</i> , 2015, 6, 14656-14668.	0.8	2

#	ARTICLE	IF	CITATIONS
928	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. <i>Oncotarget</i> , 2015, 6, 37269-37280.	0.8	135
929	Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells. <i>Oncotarget</i> , 2015, 6, 32426-32438.	0.8	16
930	Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells. <i>Oncotarget</i> , 2016, 7, 12806-12822.	0.8	10
931	Therapeutic vaccination strategies to treat nasopharyngeal carcinoma. <i>Chinese Clinical Oncology</i> , 2016, 5, 23-23.	0.4	30
932	PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study. <i>Translational Cancer Research</i> , 2020, 9, 5315-5322.	0.4	7
933	The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. <i>Current Cancer Drug Targets</i> , 2015, 15, 652-664.	0.8	33
934	Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines. <i>Current Topics in Medicinal Chemistry</i> , 2015, 16, 291-313.	1.0	2
935	Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 768-776.	0.9	6
936	Modulation of the interplay between p53, ICAM-1 and VEGF in drug-treated LoVo colon cancer cells. <i>Romanian Biotechnological Letters</i> , 2019, 24, 261-270.	0.5	5
937	Nanoparticles for Effective Combination Therapy of Cancer. <i>International Journal of Nanotechnology and Nanomedicine</i> , 2016, 1, .	1.0	11
938	HPMA Copolymer-Based Polymer Conjugates for the Delivery and Controlled Release of Retinoids. <i>Physiological Research</i> , 2016, 65, S233-S241.	0.4	8
939	Cancer Stem Cell Microenvironment Models with Biomaterial Scaffolds In Vitro. <i>Processes</i> , 2021, 9, 45.	1.3	8
940	Immunotherapy a New Hope for Cancer Treatment: A Review. <i>Pakistan Journal of Biological Sciences</i> , 2018, 21, 135-150.	0.2	21
941	Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies. <i>World Journal of Gastrointestinal Oncology</i> , 2015, 7, 338.	0.8	41
942	Cancer immunotherapy in clinical practice: the past, present, and future. <i>Chinese Journal of Cancer</i> , 2014, 33, 445-457.	4.9	38
943	Anticancer Effect of COX-2 Inhibitor DuP-697 Alone and in Combination with Tyrosine Kinase Inhibitor (E7080) on Colon Cancer Cell Lines. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 3113-3121.	0.5	8
944	Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy. <i>Journal of Biomedical Research</i> , 2016, 30, 322-33.	0.7	23
945	Tumor microenvironment and nanotherapeutics: intruding the tumor fort. <i>Biomaterials Science</i> , 2021, 9, 7667-7704.	2.6	30

#	ARTICLE	IF	CITATIONS
946	Immunotherapeutic Role of NOD-2 and TLR-4 Signaling as an Adjunct to Antituberculosis Chemotherapy. <i>ACS Infectious Diseases</i> , 2021, 7, 2999-3008.	1.8	7
947	Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis. <i>European Journal of Cancer</i> , 2021, 159, 259-274.	1.3	50
948	Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma. <i>Cancers</i> , 2021, 13, 4977.	1.7	5
949	Cancer Patients at Risk for Medication-Related Osteonecrosis of the Jaw. A Case and Control Study Analyzing Predictors of MRONJ Onset. <i>Journal of Clinical Medicine</i> , 2021, 10, 4762.	1.0	8
950	Wrapping <i>Porphyromonas gingivalis</i> for tumor microenvironment immunomodulation and photothermal immunotherapy. <i>Nano Today</i> , 2021, 41, 101311.	6.2	19
951	Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer. <i>Biomaterials</i> , 2021, 279, 121182.	5.7	22
952	Cancer-Specific Ligand-Receptor Interactions. , 2013, , 461-507.		0
953	Immune Cells Within the Tumor Microenvironment. , 2014, , 1-23.		2
955	Immune Surveillance and Cancer Pathogenesis. , 2015, , 9-20.		0
958	Targeting Multiple Signaling Pathways, a Potential Explanation to the Therapeutic Actions of Traditional Chinese Medicine in Cancer?. <i>Translational Medicine (Sunnyvale, Calif)</i> , 2015, 05, .	0.4	0
961	Introduction and background biology. , 2016, , 1-13.		0
962	T-Cell Mediated Immunomodulation and Transplant Optimization. , 2017, , 223-235.		0
963	Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R. , 2017, , 1-31.		0
964	Altered Signal Transduction Pathways in Melanoma. , 2017, , 177-207.		0
965	Synergetic immunotherapies and current molecular targets in oral cancer treatment. <i>Journal of Dr NTR University of Health Sciences</i> , 2017, 6, 73.	0.0	0
967	Investigation of Live Attenuated Measles Virus Vaccine as Anti Tumor Agent. <i>Journal of Al-Nahrain University-Science</i> , 2017, 17, 144-154.	0.1	0
969	Gene Therapy for Prostate Cancer: Current Status and Future Prospects. , 2018, , 397-406.		0
970	Adaptor protein Ruk/CIN85 modulates resistance to doxorubicin of murine 4T1 breast cancer cells. <i>Ukrainian Biochemical Journal</i> , 2018, 90, 94-100.	0.1	4

#	ARTICLE	IF	CITATIONS
973	Renal Cell Carcinoma: Oncologist Point of View. , 2020, , 21-29.		0
974	Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors. Current Drug Discovery Technologies, 2020, 17, 213-224.	0.6	3
975	Effects of Thymoquinone and Iksan 526 callus Extract on B16F10 and A375 Cell Lines. International Journal of Pharmacology, 2020, 16, 479-491.	0.1	1
976	Importance of Understanding Immune Reaction and Pharmacokinetic on the Development of Liposomal DDS Formulations. Oleoscience, 2020, 20, 71-76.	0.0	0
977	Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. Anti-Cancer Drugs, 2021, 32, 74-81.	0.7	4
978	Synergistic Effects of Metformin-Lapatinib Combination on the Expression of Bax in SK-BR3 Cells. Jentashapir Journal of Cellular and Molecular Biology, 2020, 11, .	0.1	0
979	Safety and efficacy of programmed cell deathâ€”1 antibody SHRâ€”1210 combined with concurrent chemoradiotherapy to treat locally advanced esophageal squamous cell carcinoma: a study protocol for an exploratory singleâ€”arm phaseâ”Ib trial. Precision Radiation Oncology, 2020, 4, 113-119.	0.4	0
980	Envisioning the Application of Systems Biology in Cancer Immunology. , 2020, , 599-624.		0
981	CHAPTER 14. Cell and Immune Therapy. RSC Detection Science, 2020, , 303-344.	0.0	0
983	Antibody-drug conjugates: an evolving approach for melanoma treatment. Melanoma Research, 2021, 31, 1-17.	0.6	4
984	Regulation of cancer stem cell activities by tumor-associated macrophages. American Journal of Cancer Research, 2012, 2, 529-39.	1.4	24
985	Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy. Translational Lung Cancer Research, 2013, 2, 415-22.	1.3	2
987	Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology. Integrative Medicine, 2014, 13, 32-44.	0.1	24
988	Expression and significance of Nodal in human cancers: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 20227-35.	1.3	6
990	Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes. American Journal of Translational Research (discontinued), 2017, 9, 454-465.	0.0	12
991	Nanoparticles for Effective Combination Therapy of Cancer. , 2016, 1, .		6
992	Endothelin: Ominous Player in Breast Cancer. , 2016, 1, .		4
993	Role of Lactoferrin in the Carcinogenesis of Triple-Negative Breast Cancer. , 2016, 1, .		2

#	ARTICLE	IF	CITATIONS
994	Synthesis, Pharmacological Evaluation, and In-Silico Studies of Thiophene Derivatives. <i>Oncologie</i> , 2021, 23, 493-514.	0.2	11
995	Injectable and Biodegradable Chitosan Hydrogel-Based Drug Depot Contributes to Synergistic Treatment of Tumors. <i>Biomacromolecules</i> , 2021, 22, 5339-5348.	2.6	17
996	Interaction of Supramolecular Congo Red and Congo Red-Doxorubicin Complexes with Proteins for Drug Carrier Design. <i>Pharmaceutics</i> , 2021, 13, 2027.	2.0	6
997	BDNF expression in GISTs predicts poor prognosis when associated with PD-L1 positive tumor-infiltrating lymphocytes. <i>Oncolmmunology</i> , 2021, 10, 2003956.	2.1	3
998	Harnessing Focal Adhesions to Accelerate p53 Accumulation and Anoikis of A549 Cells Using Colloidal Self-Assembled Patterns (cSAPs). <i>ACS Applied Bio Materials</i> , 2022, 5, 322-333.	2.3	6
999	Imatinib Mesylate Exerted Antitumor Effect by Promoting Infiltration of Effector T Cells in Tumor. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 34-41.	0.6	4
1000	Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association. <i>Nature Communications</i> , 2022, 13, 42.	5.8	27
1001	Combination of virotherapy and chemotherapy with optimal control for combating cancer. <i>Mathematics and Computers in Simulation</i> , 2022, 194, 460-488.	2.4	5
1002	Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?. <i>Cancers</i> , 2022, 14, 644.	1.7	11
1003	Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy. <i>Theranostics</i> , 2022, 12, 434-458.	4.6	154
1004	The mechanism underlying arsenic-induced PD-L1 upregulation in transformed BEAS-2B cells. <i>Toxicology and Applied Pharmacology</i> , 2022, 435, 115845.	1.3	4
1005	Nanozyme-Based Enhanced Cancer Immunotherapy. <i>Tissue Engineering and Regenerative Medicine</i> , 2022, 19, 237-252.	1.6	24
1006	Impact of Pretransplant Malignancy on Heart Transplantation Outcomes: Contemporary United Network for Organ Sharing Analysis Amidst Evolving Cancer Therapies. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008968.	1.6	4
1007	Enhanced Anti-Proliferative Effect of Carboplatin in Ovarian Cancer Cells Exploiting Chitosan-Poly (Lactic Glycolic Acid) Nanoparticles. <i>Recent Patents on Nanotechnology</i> , 2023, 17, 74-82.	0.7	3
1008	Semiconducting Polymer Nano-regulators with Cascading Activation for Photodynamic Cancer Immunotherapy. <i>Angewandte Chemie</i> , 2022, 134, .	1.6	9
1009	Semiconducting Polymer Nano-regulators with Cascading Activation for Photodynamic Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	58
1010	Benzothiazole-decorated iridium-based nanophotosensitizers for photodynamic therapy of cancer cells. <i>Dalton Transactions</i> , 2022, 51, 3666-3675.	1.6	7
1011	Insight into the influence of the polymerization time of polydopamine nanoparticles on their size, surface properties and nanomedical applications. <i>Polymer Chemistry</i> , 2022, 13, 235-244.	1.9	6

#	ARTICLE	IF	CITATIONS
1012	miR-30d-5p: A Non-Coding RNA With Potential Diagnostic, Prognostic and Therapeutic Applications. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 829435.	1.8	4
1013	Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study. <i>Future Oncology</i> , 2022, 18, 1461-1471.	1.1	2
1014	Nanovaccines with cell-derived components for cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 182, 114107.	6.6	41
1015	Recent applications of cell-penetrating peptide guidance of nanosystems in breast and prostate cancer (Review). <i>Oncology Letters</i> , 2022, 23, 103.	0.8	5
1016	Immune cell targeting nanoparticles: a review. <i>Biomaterials Research</i> , 2021, 25, 44.	3.2	30
1017	Regulatory landscape in the approval of cancer vaccine. , 2022, , 325-348.		0
1018	In vitro assessment of stearyl triphenyl phosphonium toxicity in drug-resistant tumor cells. <i>4open</i> , 2022, 5, 6.	0.1	1
1019	AIM in Oncology. , 2022, , 1263-1273.		0
1020	Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers. <i>Pharmaceuticals</i> , 2022, 15, 295.	1.7	7
1021	Asymmetric, amphiphilic RGD conjugated phthalocyanine for targeted photodynamic therapy of triple negative breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 64.	7.1	12
1022	Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 68.	3.5	115
1023	An Engineered Nanocomplex with Photodynamic and Photothermal Synergistic Properties for Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2286.	1.8	10
1024	Breaking Immunosuppressive Barriers by Engineered Nanoplatfoms for Turning Cold Tumor to Hot. <i>Advanced Therapeutics</i> , 2022, 5, .	1.6	3
1025	Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. <i>Genes and Diseases</i> , 2023, 10, 1367-1401.	1.5	152
1026	Clear cell renal cell carcinoma with stage IV cavoatrial tumour thrombus extension and rapid metastatic reoccurrence postsurgical treatment with review of current treatment strategies. <i>BMJ Case Reports</i> , 2022, 15, e248156.	0.2	1
1027	SIRT7 is a Prognostic Biomarker in Kidney Renal Clear Cell Carcinoma That is Correlated with Immune Cell Infiltration. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3167-3182.	0.8	0
1028	Treatment with sorafenib plus camrelizumab after splenectomy for primary splenic angiosarcoma with liver metastasis: A case report and literature review. <i>World Journal of Clinical Cases</i> , 2022, 10, 2818-2828.	0.3	1
1029	A Target Animal Effectiveness Study on Adjuvant Peptide-Based Vaccination in Dogs with Non-Metastatic Appendicular Osteosarcoma Undergoing Amputation and Chemotherapy. <i>Cancers</i> , 2022, 14, 1347.	1.7	7

#	ARTICLE	IF	CITATIONS
1030	Nanomedicine-Based Delivery Strategies for Breast Cancer Treatment and Management. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2856.	1.8	36
1031	Drugs and Drug Candidates for the Treatment of Lymphoma. , 0, , .		0
1032	Testicular Tissue Banking for Fertility Preservation in Young Boys: Which Patients Should Be Included?. <i>Frontiers in Endocrinology</i> , 2022, 13, 854186.	1.5	15
1033	Treatment with sorafenib plus camrelizumab after splenectomy for primary splenic angiosarcoma with liver metastasis: A case report and literature review. <i>World Journal of Clinical Cases</i> , 2022, 10, 2816-2826.	0.3	0
1034	Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 1757-1775.	1.1	14
1035	Design and synthesis of new 2-oxoquinoxaliny-1,2,4-triazoles as antitumor VEGFR-2 inhibitors. <i>Bioorganic Chemistry</i> , 2022, 121, 105696.	2.0	11
1036	Toripalimab in Combination With Induction Chemotherapy and Subsequent Chemoradiation as First-Line Treatment in Patients With Advanced/Metastatic Esophageal Carcinoma: Protocol for a Single-Arm, Prospective, Open-Label, Phase II Clinical Trial (TR-EAT). <i>Frontiers in Oncology</i> , 2022, 12, 878851.	1.3	1
1037	Photothermal MnO ₂ nanoparticles boost chemo-photothermal therapy-induced immunogenic cell death in tumor immunotherapy. <i>International Journal of Pharmaceutics</i> , 2022, 617, 121578.	2.6	19
1038	Critical clinical gaps in cancer precision nanomedicine development. <i>Journal of Controlled Release</i> , 2022, 345, 811-818.	4.8	13
1039	Arming Immune Cell Therapeutics with Polymeric Prodrugs. <i>Advanced Healthcare Materials</i> , 2021, , 2101944.	3.9	1
1041	Combining Chemotherapy with Immunotherapy in Colorectal Cancer: A Review. <i>Clinical Cancer Drugs</i> , 2021, 8, 10-17.	0.3	0
1042	A uracil auxotroph <i>Toxoplasma gondii</i> exerting immunomodulation to inhibit breast cancer growth and metastasis. <i>Parasites and Vectors</i> , 2021, 14, 601.	1.0	12
1044	Decorating Bacteria with Triple Immune Nanoactivators Generates Tumor-Resident Living Immunotherapeutics. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	38
1045	Combined targeted therapy and immunotherapy in anaplastic thyroid carcinoma with distant metastasis: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 3849-3855.	0.3	4
1046	Decorating Bacteria with Triple Immune Nanoactivators Generates Tumor-Resident Living Immunotherapeutics. <i>Angewandte Chemie</i> , 2022, 134, .	1.6	2
1047	Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112949.	2.5	6
1057	Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	9
1059	Recent Advances in Engineering Nanomedicines for Second Near-Infrared Photothermal-Combinational Immunotherapy. <i>Nanomaterials</i> , 2022, 12, 1656.	1.9	9

#	ARTICLE	IF	CITATIONS
1060	Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments. <i>Cancers</i> , 2022, 14, 2408.	1.7	15
1061	Efficacy of instillation of MB49 cells and thermoreversible polymeric gel in urothelial bladder carcinoma immunization. <i>Laboratory Animal Research</i> , 2022, 38, 11.	1.1	2
1062	Self-assembled nanospheres mediate phototherapy and deliver CpG oligodeoxynucleotides to enhance cancer immunotherapy of breast cancer and melanoma. <i>Nano Today</i> , 2022, 44, 101498.	6.2	17
1063	Nanomedicine as a magic bullet for combating lymphoma. <i>Journal of Controlled Release</i> , 2022, 347, 211-236.	4.8	6
1065	Bayesian two-stage sequential enrichment design for biomarker-guided phase II trials for anticancer therapies. <i>Biometrical Journal</i> , 2022, , .	0.6	0
1066	Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	7
1067	Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
1068	Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 3029-3042.	2.0	9
1069	Hydrogen Sulfide Biology and Its Role in Cancer. <i>Molecules</i> , 2022, 27, 3389.	1.7	47
1070	Functional characterization and clinical significance of super-enhancers in lung adenocarcinoma. <i>Molecular Carcinogenesis</i> , 2022, 61, 776-786.	1.3	2
1071	MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy. <i>Oncolmmunology</i> , 2022, 11, .	2.1	8
1072	Active targeting redox-responsive mannosylated prodrug nanocolloids promote tumor recognition and cell internalization for enhanced colon cancer chemotherapy. <i>Acta Biomaterialia</i> , 2022, 147, 299-313.	4.1	20
1073	Targeted therapies in non-small cell lung cancer and the potential role of AI interventions in cancer treatment. <i>Biotechnology and Applied Biochemistry</i> , 2023, 70, 344-356.	1.4	3
1075	Materdicine and Medmaterial. <i>Wuji Cailiao Xuebao/Journal of Inorganic Materials</i> , 2022, 37, 1151.	0.6	6
1076	Preparation, DFT calculations, docking studies, antioxidant, and anticancer properties of new pyrazole and pyridine derivatives. <i>Journal of Biochemical and Molecular Toxicology</i> , 2022, 36, .	1.4	9
1077	Antitumor Properties of Epitope-Specific Engineered Vaccine in Murine Model of Melanoma. <i>Marine Drugs</i> , 2022, 20, 392.	2.2	0
1078	Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma. <i>Melanoma Research</i> , 2022, 32, 324-333.	0.6	6
1079	A Fully-Human Antibody Specifically Targeting a Membrane-Bound Fragment of CADM1 Potentiates the T Cell-Mediated Death of Human Small-Cell Lung Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6895.	1.8	5

#	ARTICLE	IF	CITATIONS
1080	Improved Survival and Quality of Life Through an Integrative, Multidisciplinary Oncological Approach: Pathophysiological Analysis of Four Clinical Cancer Cases and Review of the Literature. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1081	Recent Progress on the Role of Fibronectin in Tumor Stromal Immunity and Immunotherapy. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 2494-2505.	1.0	3
1082	Catalytical nano-immunocomplexes for remote-controlled sono-metabolic checkpoint trimodal cancer therapy. <i>Nature Communications</i> , 2022, 13, .	5.8	76
1083	Emerging trends in immunotoxin targeting cancer stem cells. <i>Toxicology in Vitro</i> , 2022, 83, 105417.	1.1	8
1084	EGF Receptor-Targeting Cancer Therapy Using CD47-Engineered Cell-Derived Nanoplatforms. <i>Nanotechnology, Science and Applications</i> , 0, Volume 15, 17-31.	4.6	3
1085	A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
1086	Enhancement of anticancer immunity by immunomodulation of apoptotic tumor cells using annexin A5 protein-labeled nanocarrier system. <i>Biomaterials</i> , 2022, 288, 121677.	5.7	4
1088	Decreased DNA Damage and Improved p53 Specificity of RITA Analogs. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1524-1534.	1.9	1
1089	<i>Strobilanthes crispus</i> elicits anti-tumor immunogenicity in in vitro and in vivo metastatic breast carcinoma. <i>PLoS ONE</i> , 2022, 17, e0271203.	1.1	2
1090	The A to I editing landscape in melanoma and its relation to clinical outcome. <i>RNA Biology</i> , 2022, 19, 996-1006.	1.5	5
1091	Synergistic effect of combining sunitinib with a peptide-based vaccine in cancer treatment after microenvironment remodeling. <i>Oncolmmunology</i> , 2022, 11, .	2.1	1
1092	Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1093	Curcumin-Based Nanoformulations: A Promising Adjuvant towards Cancer Treatment. <i>Molecules</i> , 2022, 27, 5236.	1.7	33
1094	Adverse Events Induced by Nivolumab Plus Ipilimumab <i>vs.</i> Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis. <i>Cancer Investigation</i> , 2022, 40, 777-788.	0.6	1
1095	Bioengineered immunomodulatory organelle targeted nanozymes for photodynamic immunometabolic therapy. <i>Journal of Controlled Release</i> , 2022, 350, 215-227.	4.8	6
1096	FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression. <i>Cancer Letters</i> , 2022, 547, 215867.	3.2	9
1097	Understanding the effect of nitrosylation on dynamics of human epidermal growth factor: a μ s simulation study. <i>Journal Physics D: Applied Physics</i> , 2022, 55, 475201.	1.3	4
1098	Regenerative Medicines for ROS-Induced Cancers Treatment. , 2022, , 2063-2077.		0

#	ARTICLE	IF	CITATIONS
1099	Recent developments in bismuth oxyhalide-based functional nanomaterials for biomedical applications. <i>Biomaterials Science</i> , 2022, 10, 5809-5830.	2.6	7
1100	Delineating the Role of PI3K Signaling Pathway in the Stem Cell Therapeutics of ROS-Induced Carcinomas. , 2022, , 2153-2177.		0
1102	Heterocycles in Breast Cancer Treatment: The Use of Pyrazole Derivatives. <i>Current Medicinal Chemistry</i> , 2023, 30, 1145-1174.	1.2	7
1103	Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1104	Emerging Approaches for the Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Therapeutic Potential of the C5a/C5aR Axis. <i>Pain and Therapy</i> , 2022, 11, 1113-1136.	1.5	4
1105	Multi-Omics Analysis Reveals the Unexpected Immune Regulatory Effects of Arsenene Nanosheets in Tumor Microenvironment. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 45137-45148.	4.0	11
1106	Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study. <i>Cancers</i> , 2022, 14, 4509.	1.7	4
1107	Transcriptome analysis of Homo sapiens and Mus musculus reveals mechanisms of CD8+ T cell exhaustion caused by different factors. <i>PLoS ONE</i> , 2022, 17, e0274494.	1.1	3
1108	DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6
1110	Ropivacaine inhibits proliferation and invasion and promotes apoptosis and autophagy in bladder cancer cells via inhibiting PI3K/AKT pathway. <i>Journal of Biochemical and Molecular Toxicology</i> , 2023, 37, .	1.4	4
1111	Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1112	Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1113	Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents. <i>Molecules</i> , 2022, 27, 6632.	1.7	10
1115	The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	93
1116	Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
1117	Trends in age and sex-specific prevalence of cancer and cancer subtypes in acute ischemic stroke from 2007-2019. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106818.	0.7	0
1119	Polymeric Nanoparticles to Entrap Natural Drugs for Cancer Therapy. <i>Environmental Chemistry for A Sustainable World</i> , 2022, , 167-211.	0.3	1
1120	Self-Assembling Peptide-Based Functional Biomaterials. <i>ChemBioChem</i> , 2023, 24, .	1.3	30

#	ARTICLE	IF	CITATIONS
1121	Targeting of non-apoptotic cancer cell death mechanisms by quercetin: Implications in cancer therapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
1122	Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 1043-1055.	1.0	1
1123	Ganoderic Acid A Enhances Tumor Suppression Function of Oxaliplatin via Inducing the Cytotoxicity of T Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2023, 23, 832-838.	0.9	3
1124	Mannosylated Polycations Target CD206 Antigen-Presenting Cells and Mediate T-Cell-Specific Activation in Cancer Vaccination. <i>Biomacromolecules</i> , 2022, 23, 5148-5163.	2.6	6
1127	Anticancer peptide Q7 suppresses the growth and migration of human endometrial cancer by inhibiting DHCR24 expression and modulating the AKT-mediated pathway. <i>International Journal of Medical Sciences</i> , 2022, 19, 2008-2021.	1.1	2
1128	Computational analysis of fusion protein of anti-HER2 scFv and alpha luffin: A new immunotoxin protein for HER2 positive cancers. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 58, .	1.2	1
1129	Mycotoxins and cellular senescence: the impact of oxidative stress, hypoxia, and immunosuppression. <i>Archives of Toxicology</i> , 2023, 97, 393-404.	1.9	8
1130	Editorial: Induced cell senescence as a therapeutic strategy for cancer treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1131	Antioxidant, Anti-Inflammatory, Anti-Menopausal, and Anti-Cancer Effects of Lignans and Their Metabolites. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15482.	1.8	25
1132	Nanoparticle-Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy. <i>Advanced Materials</i> , 2023, 35, .	11.1	29
1133	Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy. <i>Acta Biomaterialia</i> , 2023, 158, 698-707.	4.1	3
1134	Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade. <i>Cancers</i> , 2022, 14, 6150.	1.7	3
1135	Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2023, 41, 1470-1491.	0.8	46
1136	Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma. <i>Biomedicines</i> , 2023, 11, 181.	1.4	4
1137	Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211383.	1.4	3
1138	SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responses. <i>Cellular Immunology</i> , 2023, 384, 104674.	1.4	1
1140	Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1365-1379.	2.0	93
1141	Immune Pathways with Aging Characteristics Improve Immunotherapy Benefits and Drug Prediction in Human Cancer. <i>Cancers</i> , 2023, 15, 342.	1.7	0

#	ARTICLE	IF	CITATIONS
1142	Antiproliferative and apoptotic effects of conditioned medium released from human amniotic epithelial stem cells on breast and cervical cancer cells. <i>International Journal of Immunopathology and Pharmacology</i> , 2023, 37, 039463202211507.	1.0	4
1143	AI in Computational Pathology of Cancer: Improving Diagnostic Workflows and Clinical Outcomes?. <i>Annual Review of Cancer Biology</i> , 2023, 7, 57-71.	2.3	6
1144	Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
1145	Exploring pradimicin-IRD antineoplastic mechanisms and related DNA repair pathways. <i>Chemico-Biological Interactions</i> , 2023, 371, 110342.	1.7	0
1146	Overexpression of USP15/MMP3 predict poor prognosis and promote growth, migration in non-small cell lung cancer cells. <i>Cancer Genetics</i> , 2023, 272-273, 9-15.	0.2	5
1147	Nanomaterials for Therapeutic Nucleic Acid Delivery. , 2022, , 1-29.		0
1148	Mechanism-Driven and Clinically Focused Development of Botanical Foods as Multitarget Anticancer Medicine: Collective Perspectives and Insights from Preclinical Studies, IND Applications and Early-Phase Clinical Trials. <i>Cancers</i> , 2023, 15, 701.	1.7	4
1149	Priming of Colorectal Tumor-Associated Fibroblasts with Zoledronic Acid Conjugated to the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab Elicits Anti-Tumor V α 2 T Lymphocytes. <i>Cancers</i> , 2023, 15, 610.	1.7	2
1150	Acoustically-Activated Liposomal Nanocarriers to Mitigate the Side Effects of Conventional Chemotherapy with a Focus on Emulsion-Liposomes. <i>Pharmaceutics</i> , 2023, 15, 421.	2.0	8
1151	Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma. <i>Cancers</i> , 2023, 15, 863.	1.7	6
1152	Current status and perspectives of interventional clinical trials for brain metastases: analysis of ClinicalTrials.gov. <i>Radiation Oncology</i> , 2023, 18, .	1.2	1
1153	Safety and efficacy of GEMOX plus donafenib and tislelizumab as first-line therapy for advanced epithelial malignant biliary tract cancer. <i>Cancer Medicine</i> , 2023, 12, 12263-12271.	1.3	0
1154	EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2023, 119, 110001.	1.7	3
1155	The effects of encapsulation on NK cell differentiation potency of C-kit ⁺ hematopoietic stem cells via identifying cytokine profiles. <i>Transplant Immunology</i> , 2023, 77, 101797.	0.6	7
1156	The role of immunotherapy in non-clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
1157	Prognosis and personalized treatment prediction in lung adenocarcinoma: An in silico and in vitro strategy adopting cuproptosis related lncRNA towards precision oncology. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	6
1158	The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	23
1159	Lenvatinib or anti-VEGF in combination with anti-PD-1 differentially augments antitumor activity in melanoma. <i>JCI Insight</i> , 2023, 8, .	2.3	2

#	ARTICLE	IF	CITATIONS
1160	Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	8
1161	Immune checkpoint inhibitors for advanced pancreatic cancer. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	0
1162	Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer. <i>Cancers</i> , 2023, 15, 1532.	1.7	6
1163	<i>Cancer Biology</i> , , 2023, , 1-30.		0
1164	Overexpression of CHAF1A is associated with poor prognosis, tumor immunosuppressive microenvironment and treatment resistance. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
1165	Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
1166	A Comprehensive Review of the Impact of the Renin Angiotensin System in the Liver, Lung, Infectious Diseases and Cancers. , 2023, , 113-131.		0
1167	Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
1168	MCL-1 Inhibitor S63845 Distinctively Affects Intramedullary and Extramedullary Hematopoiesis. <i>Pharmaceutics</i> , 2023, 15, 1085.	2.0	0
1169	In Vitro Study on AI-enabled Precision Cocktail Drugs Design for Treating Human Colorectal Carcinoma. <i>Advanced Therapeutics</i> , 2023, 6, .	1.6	0
1170	Perceptions of prescription opioids among marginalized patients with hematologic malignancies in the context of the opioid epidemic: a qualitative study. <i>Journal of Cancer Survivorship</i> , 0, , .	1.5	0
1171	Tumor-on-a-Chip: Microfluidic Models of Hypoxic Tumor Microenvironment. , 2023, , 297-328.		0
1172	The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1173	Self-delivery photodynamic-hypoxia alleviating nanomedicine synergizes with anti-PD-L1 for cancer immunotherapy. <i>International Journal of Pharmaceutics</i> , 2023, 639, 122970.	2.6	5
1174	Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	13
1184	Transforming Diagnosis and Therapeutics Using Cancer Genomics. <i>Cancer Treatment and Research</i> , 2023, , 15-47.	0.2	1
1187	Research development of porphyrin-based metal-organic frameworks: targeting modalities and cancer therapeutic applications. <i>Journal of Materials Chemistry B</i> , 2023, 11, 6172-6200.	2.9	5
1195	Nanomaterials for Therapeutic Nucleic Acid Delivery. , 2023, , 2005-2033.		0

#	ARTICLE	IF	CITATIONS
1198	Multifunctional QDs for receptor targeting, drug delivery, and bioimaging in pancreatic cancer. <i>Nanoscale</i> , 2023, 15, 14698-14716.	2.8	5
1222	Use and application of organ-on-a-chip platforms in cancer research. <i>Journal of Cell Communication and Signaling</i> , 2023, 17, 1163-1179.	1.8	2
1229	Molecular Mechanisms of Immune Checkpoints as an Immunotherapy Tool in Hematological Malignancies. , 2024, , .		0
1240	Cardiotoxicity of Targeted Therapies: Imaging of Heart Does Matter. , 2024, , 139-145.		0
1249	Recent Advancement in Stem Cell Therapies for Cancer Treatment. , 2024, , .		0
1260	The Applications of ELISpot in the Identification and Treatment of Various Forms of Tuberculosis and in the Cancer Immunotherapies. <i>Methods in Molecular Biology</i> , 2024, , 51-58.	0.4	0